header logo image


Page 165«..1020..164165166167..170180..»

CCM can identify nerve damage in patients with long COVID, new study finds – Mobihealth News

August 17th, 2021 1:50 am

New research, released by a team based in Turkey, Qatar, and the United Kingdom, has indicated that a specialised eye exam can be used to identify long COVID.

Published in the British Journal of Ophthalmology, the research found that corneal confocal microscopy (CCM) a non-invasive eye test that conducts real-time imaging of corneal nerve fibres can also potentially be used to confirm suspected cases of long COVID by identifying specific nerve damage.

CCM is also used to identify other conditions, such as diabetic neuropathy, Parkinsons disease, multiple sclerosis, and dementia.

THE LARGER CONTEXT

Penned by researchers from Turkeys Necmettin Erbakan University, Weill Cornell Medicine-Qatar (WCM-Q), and the UKs University of Manchester, the study stated that CCM identifies corneal small nerve fibre loss and increased DCs [dendritic cells] in patients with long COVID, especially those with neurological symptoms.

As a result, CCM could be used to objectively identify patients with long COVID.

The paper added: Long COVID is characterised by a range of potentially debilitating symptoms which develop in at least 10% of people who have recovered from acute SARS-CoV-2 infection.

Symptoms of long COVID include headache, tingling and/or numbness, neuropathic pain, a loss or change in the senses of taste and smell, and so called brain fog.

WHY IT MATTERS

According to a statement by WCM-Q, nerve damage observed in the corneas using CCM can be reliably used as an indicator of nerve damage in other parts of the body.

CCMs value as a diagnostic tool is increased by a number of important factors: the test takes only a few minutes, is completely non-invasive, causes almost no discomfort for patients, utilises existing and widely available ophthalmic equipment, and can be done in the clinic.

ON THE RECORD

The predominance of neurologic symptoms in people with long COVID prompted us to investigate whether CCM could be used to objectively identify nerve damage in patients with the disease, said Rayaz Malik, professor of medicine and assistant dean for clinical investigations at WCM-Q. We are the first group in the world to report a very strong association between nerve damage observed using CCM and long COVID.

Although the majority of people had mild COVID, patients with more severe disease had evidence of greater corneal nerve damage, suggesting that the severity of nerve damage may be related to the severity of disease at presentation.

We believe CCM has the potential to serve as an extremely valuable tool to be used by physicians to help diagnose and assess the evolution of long COVID and to determine the severity in individual cases. The identification of underlying nerve damage also allows us to think about this condition as a neurodegenerative disease, which may be amenable to treatment.

Go here to read the rest:
CCM can identify nerve damage in patients with long COVID, new study finds - Mobihealth News

Read More...

Spotlight on ultrasonography in the diagnosis of PND | IJGM – Dove Medical Press

August 17th, 2021 1:50 am

Introduction

Entrapment mononeuropathies are common and contribute to considerable morbidity in the community. The most common entrapment is carpal tunnel syndrome, with an estimated incidence of 197 per 100,000 women,1,2 and much higher rates among employees in certain industries (eg, up to 42% prevalence in poultry workers).3,4 Early diagnosis is essential in entrapment mononeuropathy, to limit nerve injury and associated morbidity. Unfortunately, electrodiagnostic studies (EDX) are frequently non-localising in entrapment neuropathy, and this is the most frequent indication for nerve ultrasound in clinical practice.5 In addition, a significant proportion of EDX are non-diagnostic, between 10% and 25% in CTS for instance, depending on the severity of presentation and EDX protocol used.6,7

Separately, peripheral neuropathy (PN) represents a major cause of morbidity globally,8 and its prevalence is increasing. This has been attributed to the ageing population, an increased prevalence of diabetes and use of neurotoxic drugs such as chemotherapeutics and antiretrovirals.914 The assessment of PN has traditionally relied on neurological assessment, close review of comorbidities and EDX testing. EDX enables neuropathy to be diagnosed, providing information on the pattern of involvement, severity, distinction between axonal and demyelinating pathologies, as well as allowing prognostication and monitoring.15 The clinical and EDX assessment has several limitations however, including a lack of precise anatomical information,15 difficulty diagnosing proximal demyelinating PN,16 and difficulty in distinguishing hereditary from acquired demyelinating PN.17,18 Consequently, there is a need for newer techniques to better diagnose and monitor patients with PN.

Ultrasound using modern, high-frequency probes and image processing provides excellent visualisation of the peripheral nerve, with good spatial resolution and the ability to assess vascularisation with power Doppler. Ultrasound has the further advantage of being able to assess the entire nerve course in real time, whilst being quick, painless, non-invasive, free of radiation and relatively cheap. Ultrasound therefore provides the ideal tool for assessing PN, entrapment mononeuropathy and complements the clinical and EDX assessment. Given the rapid uptake of ultrasound by clinicians, the present review is designed as a practical resource to promote an understanding of the basics of peripheral nerve ultrasound as well as current and emerging applications of ultrasound in the diagnosis of neurological disease.

An ultrasound system uses a transducer to convert electrical current into ultrasound waves via the piezoelectric effect. These waves travel through tissue and are either reflected, refracted, scattered, or absorbed. The amount of resistance an ultrasound beam experiences as it travels through a tissue is referred to as acoustic impedance and is dependent on tissue density. The degree of ultrasound reflection is dependent on the relative differences in tissue densities at a tissue interface, as well as the angle of insonation. Reflected waves are recorded by the transducer and converted into electrical energy which is used to generate our image. The brightness of this image is labelled echointensity (EI) and is proportional to the amount of reflection. This signal is amplified (gain), which can be adjusted. Anisotropy is the loss of echogenicity when an ultrasound beam is not perpendicular to the structure imaged and can be exploited to distinguish peripheral nerves (low anisotropy) from adjacent structures such as tendons (high anisotropy).

The ultrasound image resolution is determined largely by the frequency of the waves, recorded in megahertz (MHz). Higher frequencies allow for greater image resolution, and frequencies greater than 12 MHz are typically utilised for peripheral nerve imaging. In contrast, higher frequencies undergo greater attenuation at increasing depths, and therefore lower frequency ultrasound with better penetration is preferable when imaging deeper structures such as muscle. Consequently, ultrasound imaging is a trade-off between resolution and penetrance, which is achieved in neuromuscular ultrasound by using a transducer with a range of frequencies, for example, 186 MHz. Linear array transducers are typically used in neuromuscular diagnosis, providing a narrower field of view but better resolution at the edges of an image than curvilinear transducers. A smaller footprint probe is sometimes desirable when imaging structures where only limited contact between a probe and the body surface is possible, for instance the hands and feet.

The appearance of peripheral nerves on ultrasound correlates with the microscopic and macroscopic anatomy.19 When viewed longitudinally nerves appear as linear hypoechoic fascicles surrounded by hyperechoic perineurial connective tissue, both enclosed by the bright epineurial connective tissue layer (Figure 1). In cross section, nerves take on a honeycomb appearance of rounded hypoechoic fascicles surrounded by hyperechoic connective tissue (Figure 1). The size and fascicular pattern of healthy nerves can vary depending on location. More proximal nerve segments are typically larger in cross-sectional area (CSA) with fewer or no fascicles, meaning they appear more hypoechoic. This is the result of densely packed fascicles with less connective tissue.20 This process also occurs at fibro-osseous boundaries, for instance the ulnar nerve at the level of the medial epicondyle also appears relatively more hypoechoic even in normal limbs21 (Figure 2D).

Figure 1 Ultrasound appearance of normal nerves. Ulnar nerve imaged in axial/cross-sectional view with honeycomb pattern (A) and longitudinal view with tram track pattern (B).

Figure 2 Normal ulnar nerve and ulnar artery (artery denoted *) in cross section at the wrist (A) in Guyons canal. Ulnar nerve in cross section in the forearm (B), cubital tunnel between two heads of flexor carpi ulnaris (FCU) muscle (C) and between the medial epicondyle (**) and olecranon at the elbow (D).

When differentiating nerves from other structures the following key features can be utilised. Firstly, nerves are surrounded by a hyperechoic rim due to epineurial connective tissue. Secondly, they are more anisotropic than muscle and tendons, meaning tilting the transducer will markedly change the echointensity of these other structures when compared to nerves. Thirdly, unlike blood vessels they are non-compressible, with no pulsatile movement or Doppler flow.

There are several characteristic sonographic features in peripheral nerve injury, including changes in nerve size, echointensity, fascicle dimensions, epineurial boundaries and Doppler signal. Peripheral nerve size increases focally with entrapment and more diffusely in some patients with PN. The cross-sectional area (CSA), measured by tracing inside the hyperechoic epineurium, has a high inter and intraobserver reliability and is highly reproducible.22 The CSA has been widely used to quantify PN, by reference to established normal values for several key peripheral nerves and the brachial plexus.2326 It is important to adjust CSA for normal variability seen across age, sex, height, and BMI.23,24

Echointensity is typically reduced in nerve injury and is usually assessed qualitatively and is usually associated with loss of the normal fascicular architecture described above. Nerve echogenicity can be measured quantitatively using mean gray-scale analysis.21,27,28 Quantitative measures are specific to the individual ultrasound machine used to establish the normative data, limiting their broader application, unless values are normalized using standardized phantoms.

Improvements in ultrasound technology has facilitated measurement of individual nerve fascicles,29 for instance ultra-high frequency ultrasound can identify increased fascicular diameter in immune-mediated PN.30 Fascicular architecture varies from person to person, nerve to nerve and from one anatomical location to another, and there is more work needed to characterise this metric in health and disease.

The Doppler effect is a change in ultrasound frequency reflected from an object, such as a red blood cell, moving toward or away from the transducer. This can be used to demonstrate changes in vascularity of peripheral nerves and surrounding structures. Normal nerve does not have any detectable blood flow. Hence, the presence of Doppler flow is abnormal in peripheral nerves and indicates hypervascularity, which has been described in compressive and inflammatory and some axonal neuropathies.3133

Elastography is a technique used to determine the elasticity of tissue. This is in the form of either strain elastography, in which tissue displacement from extrinsic compression or ambient tissue oscillations is used, or shear wave elastography (SWE), produced by acoustic radiation force impulses generated by the ultrasound probe. Peripheral nerve injury involves the destruction of myelin, which is more compliant, and a proliferation of stiff connective tissue.34 This results in increased stiffness on elastography. There are now several studies supporting the role of both strain and shear wave elastography in diagnosing carpal tunnel syndrome, ulnar neuropathy at the elbow, diabetic PN and even optic neuropathy.35 Further research is ongoing to assess the ability of elastography to diagnose nerve injury in preclinical neuropathy, and to evaluate elastography as a monitoring tool for longitudinal assessment.

Peripheral nerve compression results in nerve enlargement proximal /or distal to the entrapment site on cross-sectional imaging and can appear as an hourglass configuration on longitudinal views (Figure 3).5,36,37 The entrapped nerve may also appear flattened, hypoechoic, immobile and hypervascular.3739 Importantly, up to 42% of mononeuropathy cases studied with ultrasound detect a pathology that alters diagnosis or management, for instance nerve strictures, ganglion cysts or other intraneural or extraneural lesions.40

Figure 3 Normal median nerve and flexor tendons (*) in cross section (A) and longitudinal view (B). Normal median nerve in the forearm (C) superficial to flexor digitorum profundus (FDP) and deep to flexor digitorum superficialis (FDS) muscles. Abnormal median nerve at the wrist (D) with hourglass constriction (white arrows) with swelling proximally at the carpal tunnel entrance (**).

Interestingly, a Sonographic Tinel sign may be present, with clinical symptoms elicited by mechanical pressure from the ultrasound probe at a compression site. Of further interest, chronic nerve compression may result in neurogenic changes to the muscle supplied, such as hyperechogenic and eventually atrophied muscle with fasciculations. The sonographic findings for specific mononeuropathies are summarised below and in Table 1.

Table 1 Diagnostic Sonographic Findings in Compressive Mononeuropathies

The median nerve is optimally studied with the patient seated or lying with the palm facing upward. Imaging can begin at the distal wrist crease, with a cross-sectional view of the median nerve at the entry to the carpal tunnel. The nerve can then be traced proximally as it dives between the flexor digitorum superficialis and profundus in the forearm, and then between the two heads of the pronator teres (another potential site of entrapment).41,42 At the elbow, it runs with the brachial artery, and it can be traced with the artery up to the axilla.

Carpal tunnel syndrome (CTS) results in increased median nerve CSA at the wrist (Figure 3). The ratio of CSA between the wrist and forearm (12 cm proximal to the distal wrist crease), known as wrist to forearm ratio (WFR) will also be increased (Table 1). The median nerve may also be swollen distally at the carpal tunnel outlet, and scanning this region increases the diagnostic sensitivity by 15%20%.43,44 The presence of an immobile, hypoechoic or hypervascular median nerve at the wrist also aids in diagnosis.39 There are several clinical and EDX mimics for CTS, such as benign tumours (neuroma, schwannoma, hamartomas), ganglion cysts, thrombosed vessels or tenosynovitis.45 These are easily diagnosed with ultrasound.45,46 A bifid median nerve can also be identified, which is more prevalent in patients with CTS.47 Ultrasound is useful to assess persistent symptoms post-surgical carpal tunnel release, where it can detect a compressive post-operative scar, a residual anatomical constriction point suggesting incomplete release or an alternative cause for neuropathy.48

In addition, ultrasound can localise a proximal median nerve injury and may help establish a cause, such as entrapment by the ligament of Struthers,49 pronator teres muscle,50 or an accessory palmaris longus muscle,51 as well as vascular pathology52 and iatrogenic injury.53

The ulnar nerve is ideally studied with the elbow flexed at 90 degrees, palm facing upwards and the patient either seated or supine. The Ulnar nerve can be easily located at the elbow in the groove between the olecranon and the medial epicondyle of the humerus (Figure 2C). The nerve can be traced proximally as it runs between the biceps brachii and medial head of triceps brachii en route to join the axillary artery. The nerve can then be traced from the elbow distally as it travels between the two heads of the flexor carpi ulnaris muscle (forming the cubital tunnel) (Figure 2C), before travelling between the flexor digitorum profundus and superficialis as it approaches the ulnar artery (Figure 2B). The ulnar nerve together with the ulnar artery enter the hand superficially via the guyons canal (Figure 2A).

Approximately 76% of ulnar neuropathies are localised to the olecranon groove54 and are typically caused by extrinsic compression or stretch of the nerve resulting in focal demyelination. Focal increase in the ulnar nerve CSA at or above the olecranon is diagnostic.55 The next most common site for injury is at the cubital tunnel due to ulnar nerve entrapment, referred to as cubital tunnel syndrome. Ultrasound demonstrating focal nerve constriction at the entry to the tunnel with proximal swelling is diagnostic. Longitudinal views can aid in localising compression. Both the degree of swelling and hypervascularity are markers of severity56 and axonal loss.57,58 It is important to differentiate cubital tunnel entrapment from compression in the olecranon groove because the former is amenable to surgical release.59 Less common aetiology of ulnar nerve injury can also be identified with ultrasound, including Struthers arcade compression in the upper arm,60 ganglion at the elbow, benign tumours, abscess or anomalous muscles (anconeus epitrochlearis).55 Dynamic ultrasound can also detect a subluxing ulnar nerve, which refers to the migration of the ulnar nerve to the medial epicondyle tip with elbow flexion. Studies assessing the causative role of this abnormality in ulnar neuropathy are conflicting.6163 An elegant study by Omejec et al demonstrated higher rates of ulnar nerve subluxation in patients without a clinical neuropathy, especially those with subclinical ulnar nerve changes on EDX.64

A common dilemma when assessing ulnar neuropathy electrodiagnostically is the inability to localise the dysfunction, and between 14% and 25% of EDX studies are non-localising.65,66 Importantly, the majority of these electrodiagnostically non-localising ulnar neuropathies can be localised with ultrasound.65,66 In addition, ultrasound can readily diagnose ulnar nerve injury at Guyons canal for example due to cycling-related wrist compression,67 intraneural ganglion cyst68 or ulnar artery thrombosis.69

The radial nerve is best imaged with the elbow flexed and the dorsal upper arm directed toward the examiner, so that the posterior course of the nerve above the elbow can be easily traced. The nerve is readily identified in the lateral antecubital fossa, lying above the brachialis and beneath the brachioradialis muscles (Figure 4A). At this location, the nerve starts to divide into the superficial and deep branches. The radial nerve can be traced proximally as it wraps behind the humerus. The radial nerve is then followed up to the spiral groove, between the medial and lateral heads of the triceps brachii muscle (Figure 4B). The nerve can be traced from the antecubital fossa distally as it divides. The superficial branch travels laterally, beneath the brachioradialis and next to the radial artery, before perforating the extensor facia in the distal forearm to reach the anatomical snuff box and provides sensation to the dorsolateral hand and dorsal aspect of digits 13. The deep branch travels medially and dives through the arcade of Frohse (a fibrous arch extending from supinator muscle to lateral epicondyle) as it pierces the supinator muscle (Figure 4C). The nerve then becomes the posterior interosseus nerve travelling over the interosseus membrane and supplying the extensor compartment of the forearm.

Figure 4 Posterior interosseus nerve (PIN) and Superficial radial nerve (SRN) branches of the radial nerve in the cubital fossa (A). Radial nerve branches deep to brachioradialis and superficial to brachialis muscles. Cross section of normal radial nerve in the spiral groove between the triceps muscle and humerus bone (B). Posterior interosseus nerve travelling between the two heads of supinator muscle (*) overlying the proximal radius bone (C). Cross section of abnormal enlarged radial nerve in spiral groove with CSA measuring 35 mm2 (D).

The commonest cause of radial neuropathy is compression at the spiral groove due to extrinsic pressure, known as the Saturday night palsy because it may be associated with sleeping awkwardly when sedated. Ultrasound will show focally increased radial nerve CSA in the spiral groove (Figure 4D). This can be based on absolute increase in CSA or side-to-side comparison (Table 1). Swelling in the radial groove also has prognostic value and predicts a worse clinical outcome at 3 months then radial palsy with normal nerve calibre.70 Another common cause for proximal radial neuropathy is a humeral shaft fracture. Nerve injury secondary to fracture is readily diagnosed with ultrasound.71 The deep motor branch, the posterior interosseus nerve, can be injured at the arcade of Frohse. Causes of this Posterior Interosseus Syndrome may be diagnosed with ultrasound including iatrogenic injury,72 ganglion cysts,73,74 vascular abnormalities,75 tumours76 and entrapment from other structures.77 The superficial radial sensory nerve is susceptible to injury from extrinsic compression, trauma, or mass lesions7880 which may be seen on ultrasound.

The fibular nerve can be identified on ultrasound by first imaging the sciatic nerve in the proximal popliteal fossa (Figure 5A) and tracing it distally as it bifurcates into the fibular (lateral) and tibial (medial) nerves (Figure 5B). The common fibular nerve can then be traced around the head of the fibular bone (Figure 5C). An enlarged and hypoechoic nerve at the fibular head support a diagnosis of compression,24,8183 although care must be taken to not image the nerve obliquely at this location. The deep and superficial fibular nerve branches are more difficult to visualise distally due to their small size and depth, although the deep fibular nerve is readily identified in the anterior ankle. The most common cause for fibular nerve injury at the fibular head is stretch or contusion,84 often associated with significant weight loss, sustained immobility and excessive leg crossing.85,86 However, in one series, as many as 18% of patients presenting with foot drop, have an intraneural ganglion of the fibular nerve identifiable with ultrasound.87 Entrapment of the fibular nerve in the fibular tunnel is a rare cause of fibular neuropathy,88 but this can be seen on ultrasound as a focal stricture of the nerve just prior to the fibular (Figure 5). It is critical to image patients with fibular neuropathy to exclude entrapment and intraneural ganglion, as these patients require surgical decompression whereas non-operative management is indicated for other causes.

Figure 5 Cross-sectional view of the normal sciatic nerve in the distal thigh (A), fibular and tibial nerves in the popliteal fossa (B), fibular nerve at the fibular head (C) and tibial nerve just above the ankle, * denote the ulnar artery (D).

The tibial nerve can also be identified in the popliteal fossa (Figure 5B) before it dives between the heads of the gastrocnemius muscle. The patient is usually examined in the prone position. The tibial is more difficult to identify when running deep in the calf due to the overlying gastrocnemius and soleus muscles but the nerve can be imaged distally as it travels behind the medial epicondyle of the ankle, beneath the flexor reticulum (also known as the tarsal tunnel), in the company of the posterior tibial vessels, tibialis posterior, flexor digitorum longus and flexor hallucis longus tendons. The tibial nerve then branches into the medial and lateral plantar nerves to innervate the sole of the foot.

Ultrasound can identify a cause for distal tibial neuropathy in up to 94% of presentations.89 In one series of 81 ultrasound cases the most prevalent causes were varicose plantar veins, static foot disorders, epineurial ganglion cysts, neuropathies, and iatrogenic injuries. Tarsal tunnel syndrome is a rare compressive mononeuropathy which may be diagnosed on ultrasound by demonstrating an enlarged tibial nerve CSA within the tunnel (Table 1). Ultrasound may also detect a cause in proximal tibial neuropathies, such as bakers cyst90 or soleus arcade/sling.91,92

After significant nerve trauma we may see axonotmesis with interruption of axons but intact connective tissue which acts to guide axonal regrowth. If severe axonotmesis occurs, axonal regrowth occurs proximal to distal at a rate of 1 mm per day. Alternatively, nerve trauma may result in neurotmesis with interruption of both axon and connective tissue. In this circumstance, axonal regeneration is precluded by scar tissue.93 There are several limitations to clinical and EDX evaluation of traumatic peripheral nerve injury. EDX in the acute setting cannot differentiate between a nerve with damaged axons but intact connective tissue and a complete nerve transection.94 This is crucial, however, because complete transection can improve with time-critical surgical intervention. In addition, without imaging one cannot identify other specific anatomical lesions that may require surgery, for instance a painful chronic neuroma,95 or ongoing nerve injury from bone spurs, haematoma, or surgical hardware.96

Importantly, ultrasound can assist in diagnosing and localising a traumatic peripheral nerve injury.95,96 This is visualised by focal swelling and reduced echogenicity, altered fascicular architecture, discontinuity97 or neuroma formation.95 In addition, ultrasound allows the detection of muscle hyperintensity and atrophy secondary to nerve trauma, which often precedes other sonographic and EDX changes.98 In addition, ultrasound can be used to assess whether surgical intervention is required in the setting of nerve discontinuity,96 neuromas99 or bony entrapment.100,101 It is worth noting that ultrasound will not differentiate between severe axonal injury with and without intact epineurium.

Ultrasound also plays a role in surgical planning, by identifying the exact location and length of nerve injury as well as associated structures.20,96,102 Intraoperative high-resolution nerve ultrasound monitoring can also be used103 as it matches closely with intraoperative neurophysiological and neuropathological findings. Following surgical peripheral nerve repair104 ultrasound has a role in identification of partial discontinuity, neuroma formation and compression by overlying scars that may require surgical re-exploration. In a retrospective series of 143 consecutively imaged traumatic peripheral nerve injuries96 ultrasound was 90% sensitive for any nerve injury. The most common abnormalities seen were nerve swelling, followed by neuroma, scar tissue, and discontinuity. Complete nerve transections were infrequent, but readily identified by swollen nerve stumps proximally and distally. The degree of nerve swelling did not correlate with severity of motor dysfunction on EDX.

Thus, ultrasound is an important tool in diagnosing and localising nerve trauma, grading injury, determining the need for surgery and provides useful information in the intra and post-operative setting. In concert with improvements in ultrasound, MRI techniques to visualize the peripheral nervous system such as Diffusion tensor imaging (DTI) have undergone rapid development. DTI with tractography uses water diffusion anisotropy along longitudinal fibre tracts to image nerve pathways.105 DTI has the capability to image nerve injury not identified using EDX or standard imaging techniques.93 In addition, DTI can identify axonal regeneration following traumatic nerve injury with the potential to guide the need for surgical intervention.106

Generalised peripheral neuropathy may be associated with changes on nerve ultrasound. The most prominent changes are identified in demyelinating neuropathies where nerve enlargement is characteristic. Axonal neuropathies are perhaps surprisingly only infrequently associated with reduction of nerve size. The role for ultrasound in diagnosing PN is increasing, and it has the potential to streamline diagnostic algorithms, reduce the need for expensive or invasive investigations and even rationalise costly immunomodulatory and genetic therapies. The following section explores the current ultrasound findings in hereditary, immune mediated and axonal PN.

CIDP is an immune-mediated process typified by multifocal demyelinating nerve pathology in proximal and distal limbs, leading to weakness, sensory loss and reduced deep tendon reflexes. The presentation of CIDP is variable and includes atypical forms such as pure motor or pure sensory CIDP, multifocal acquired demyelinating sensory motor neuropathy (MADSAM) and distal acquired demyelinating sensory (DADS) neuropathy. Abnormal nerve morphology is identified on ultrasound in 6487% of patients.107109Typical sonographic findings are increased nerve CSA in a multifocal pattern, affecting proximal and distal segments and non-entrapment sites110 (Figure 6). Like clinical features, ultrasound findings are similarly variable, with some patients even demonstrating normal nerve size on ultrasound.107

Figure 6 Abnormal median nerve in the forearm in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), demonstrating multifocal nerve enlargement in longitudinal views (A). Heterogeneous hypo and hyperechoic fascicular enlargement seen of the same nerve in cross section (B) with CSA measuring 68 mm2. Cross sectional view of enlarged median nerve in the forearm with uniform fascicular enlargement seen in Charcot Marie Tooth Type 1A (C) with CSA measuring 62 mm2.

MADSAM is an asymmetric CIDP variant with a more asymmetrical, multifocal pattern of nerve enlargement on ultrasound.111,112 Enlarged hypoechoic fascicles are typically seen in segments with past or present conduction block112,113 and seem to reduce in response to treatment.114

Several distinct ultrasound patterns in CIDP have been identified which correlate with disease duration. Three ultrasound classes were described by Padua et al108 based on CSA and echogenicity. Large hypoechoic nerves (class 1) were associated with the shortest disease duration (04 years) when compared to normal size nerve with hyperechoic changes (class 3) (711 years duration). Large nerves with heterogeneous hypo- and hyperechoic fascicles (class 2) were also heterogenous regards disease duration (0.516 years).

Ultrasound can increase diagnostic accuracy in CIDP, especially when proximal segments and the brachial plexus are imaged.115 This is important because misdiagnosis is common in CIDP, especially in the atypical variants.116 One prospective study assessed 100 suspected chronic immune mediated polyneuropathy referrals with EDX and ultrasound.115 Enlargement in the proximal median nerve or C5 root (referred to as the Short Ultrasound Protocol) was diagnostic with a sensitivity of 84.696.4% and specificity of 44.972.8% depending on the reference standard. Importantly, 25% (11/44) of the those ultimately diagnosed as CIDP/MMN had normal EDX but abnormal ultrasound and were responsive to immunotherapy.

Ultrasound has also been researched as a tool to differentiate between hereditary demyelinating neuropathies, CIDP and other immune mediated PN (Table 2). Various schema has been proposed to quantify these differences. CMT1A is typically associated with the largest nerves, which are homogeneously/diffusely enlarged.107,117 The pattern of enlargement is more variable and to a lesser degree in CIDP. Normal nerve calibre, focal and diffuse enlargement resembling CMT have all been described in CIDP.23,107,109,118 Mild, regional, asymmetrical or heterogenous enlargement all point towards atypical CIDP, MMN, or GBS.23,107 Various imaging protocols and scoring systems have been proposed eg, the homogeneity score and the regional nerve enlargement index.119 The more focal pattern of nerve enlargement seen in inflammatory neuropathies can also be quantified using the intranerve variability (maximum CSA/minimum CSA for a given nerve) and the internerve variability (maximum intranerve variability/minimum intranerve variability for a given patient).120 However, these patterns and scores are predominantly based on relatively small retrospective cohorts, and larger prospective studies are required to define the optimal ultrasound protocols to differentiate these disorders.119

Table 2 Diagnostic Sonographic Findings in Peripheral Neuropathies

Ultrasound provides surrogate markers for disease severity in CIDP, such as hypervascularity, number of nerves involved and cervical nerve root CSA.121,122 Larger nerve CSA has been correlated with slower conduction velocities on EDX testing in many123,124 but not all studies.125 Nerve enlargement has also been associated with clinical weakness and disability.124,125 Additionally, ultrasound provides prognostic information in CIDP, with both decreasing intra-nerve CSA variability and normal or decreasing nerve calibre predicting treatment responsiveness.126

Furthermore, ultrasound has potential as an outcome measure in CIDP. A study of 23 consecutive patients with CIDP followed with serial ultrasound measurements over 3-years, noted CSA increased in 51% of nerve segments, and was associated with increased functional disability and decreased motor nerve amplitudes on EDX.124

GBS is an acute immune mediated generalised polyneuropathy, characterised by ascending sensory disturbance and areflexic weakness, with both demyelinating (acute inflammatory demyelinating polyneuropathy AIDP) and axonal forms (acute motor/sensory axonal neuropathy AMAN/AMSAN). The nadir is typically reached by 6 weeks, and diagnosis is clinical, supported by EDX and cerebrospinal fluid studies.

Proximal nerve and nerve root enlargement has been reported on ultrasound, although the degree and frequency are less then CMT1A and CIDP.23,107 For example, mild enlargement was reported in 8/17 upper limb nerves in one cohort,23 and 5/6 patients in another cohort, although this involved only 9% of the studied nerve segments.127 Importantly, nerve enlargement can be seen as early as day 13 of symptoms,23,128 before EDX changes are apparent.23 The presence of enlarged cervical nerve roots and vagus nerves, together with normal nerve calibre elsewhere can differentiate GBS from CIDP with a positive predictive value > 85%.117 Vagal nerve enlargement on ultrasound has also been correlated with autonomic dysfunction in AIDP.128,129

Some studies have suggested ultrasound can be used to distinguish demyelinating and axonal variants of GBS,130 while other studies have found no difference.131 Mori et al demonstrated enlarged cervical and proximal nerve segments in 6 patients with AIDP, contrasting to enlarged distal nerve segments (forearm, wrist and ankle) in 9 patients with AMAN/AMSAN.130

Miller Fisher Syndrome (MFS) is a rare GBS variant characterised by the triad of ophthalmalgia, ataxia and areflexia, and is often associated with bilateral facial weakness. Hsueh et al132 reported significantly enlarged facial but normal limb nerves in MFS.

Ultrasound has been proposed as an outcome measure for treatment in GBS.129,131 Grimm and colleagues assessed 27 patients with GBS and 31 controls with ultrasound at baseline and 6 months follow up.129 Cervical spinal, medial and vagus nerves were significantly larger in GBS at baseline, but returned to normal at 6 months, except for the vagus nerve which remained enlarged in those patients with significant autonomic dysfunction.

MMN is a rare upper limb predominant demyelinating polyneuropathy characterised by slowly progressive weakness and response to treatment with intravenous immunoglobulin.133135 In practice, MMN can be difficult to distinguish from certain ALS variants.136 Sonographically mild multifocal nerve enlargement, typically in proximal sites and the brachial plexus, is seen in up to 90% MMN patients.137 Ultrasound enlargement can also occur in clinically and electrophysiologically unaffected nerve segments.137

Importantly, nerve and nerve root enlargement on ultrasound can differentiate MMN from ALS. Grimm and colleagues demonstrated that 4 enlarged nerves/nerve roots had a 87.5% sensitivity and 94.1% specificity for distinguishing MMN from ALS in their cohort.138 Others have found that ultrasound is better at distinguishing MMN from ALS then standard EDX assessments.139,140 Ultrasound can occasionally aid in the distinction of MMN from CIDP by the presence of milder, asymmetric nerve enlargement with greater side-to-side intranerve variability, although considerable overlap exists.141

Multiple studies have demonstrated a variable association between ultrasound findings and clinical weakness, disability and EDX abnormalities.139,141,142 Rattay et al demonstrated that the nerve enlargement reduced in parallel with disability after 612 months of treatment in MMN, although baseline nerve enlargement did not correlate with clinical or EDX markers of severity.143 Thus, nerve ultrasound can not only improve diagnosis but also disease monitoring in MMN.

Anti-MAG is an immune mediated demyelinating neuropathy with distally predominant symmetrical sensorimotor impairment and prolonged distal motor latencies on EDX. Despite this the ultrasound abnormalities tend to be proximal144 and there are no reports of distal nerve enlargement. Segmental nerve enlargement has been described in cervical nerve roots, brachial plexus, and proximal nerve segments145 with considerable inter-nerve variability.146 Nerve ultrasound has been used to distinguish anti-MAG neuropathy from similar pathologies. Specifically, nerve size is greater in MAG positive than MAG-negative paraproteinaemic neuropathy.146 Some cohorts found nerve calibre in MAG to be smaller than CIDP.146

POEMS is a rare paraneoplastic multisystem plasma cell disorder causing a mixed axonal and demyelinating polyneuropathy that can mimic CIDP. Pathogenesis is attributed to increased vascular endothelial growth factor leading to neovascularisation and peripheral nerve oedema.147 It is somewhat surprising then, that peripheral nerve ultrasound studies have demonstrated nerve enlargement at entrapment sites only.148 Indeed, the lack of diffuse/multifocal enlargement has been offered as a means of distinguishing POEMS from CIDP.148 However, the published cases describe nerve ultrasound in the subacute setting, after significant secondary axonal degeneration has occurred, and thus the ultrasound findings in early disease remain to be defined.

Brachial neuritis is an idiopathic monophasic inflammatory condition affecting the branches of the brachial plexus. The typical presentation is with severe pain followed by unilateral upper limb weakness. Imaging with ultrasound and other modalities, combined with surgical exploration, have led to greater pathological understanding of this condition. It is now hypothesized that a sequence of nerve enlargement, fascicular adhesion and constriction contributes to ongoing nerve injury.149 Rotational movements of the upper limb are then thought to cause the adhered nerve to tort, with fascicular entwinement and further constriction which has been associated with poor recovery.149 The most common finding on ultrasound, seen in 74% of cases, is unilateral focal nerve enlargement, often affecting the median, radial, anterior, or posterior interosseus nerves.150,151 Other findings include partial nerve constriction, fascicular entwinement or complete nerve constriction with an hourglass morphology, described in up to 50% of cases.152 Early imaging with ultrasound can potentially identify those cases with partial or complete constriction who may benefit from surgical intervention.149,151 Diaphragmatic ultrasound can be used to diagnose phrenic nerve involvement in this condition.

Mononeuritis multiplex is the characteristic pattern of peripheral nerve vasculitis both in isolated nerve and systemic vasculitic disorders. This is reflected on nerve ultrasound by focal, asymmetrically enlarged nerves, in proximal segments without extension to the brachial plexus.153155 Enlargement is described in most EDX affected nerve segments, and prominently in the tibial and fibular nerves.154,156,157 Importantly, nerve enlargement is seen in almost half of all clinically and EDX unaffected nerves.155 Hypervascularity can support a diagnosis of vasculitis PN and is reported in 19% of cases.155 The presence of an axonal neuropathy, with multifocal nerve enlargement proximal to compression sites without plexus involvement is argued to be 94% sensitive and 88% specific for vasculitis.155 Nerve enlargement might reduce with treatment, although this is based on a single case study only.153 Nerve ultrasound has also been suggested as a tool to guide nerve biopsy. Hence, ultrasound can improve diagnosis in PN vasculitis and has the potential to guide biopsy sites and support treatment monitoring.

Hereditary neuropathies are among the most studied conditions in the field of neuromuscular ultrasound. The disorders discussed below are just some of the hereditary conditions that have been studied. There are many others where no data exists.

CMT1A is the most common form of CMT, caused by an autosomal dominant duplication of the peripheral myelin protein 22 gene, resulting in a demyelinating PN. Ultrasound in CMT1A demonstrates diffuse symmetrical nerve CSA increase in 89100% of patients158160 (Figure 6C). This occurs from the brachial plexus and proximal nerve segments to the small sensory nerves such as the sural and auricular nerves.158 Nerve enlargement is detectable from as young as 19 months of age,161 and as such ultrasound is an ideal non-invasive diagnostic aid in young children. Larger CSA has been associated with more severe disease, measured with the CMT neuropathy score.158,162 In addition, a number of studies have demonstrated a correlation between the degree of nerve enlargement and neurophysiological dysfunction,158,162 although this has not been a universal finding.159

CMT1B is another demyelinating form of CMT, due to Myelin Protein Zero mutations. Ultrasound in CMT1B demonstrates nerve enlargement proximally,163,164 but reduced CSA in the lower limbs, helping to distinguish it from CMT1A.164 CMT1X is an X linked mutation of the gap junction associated protein and demonstrates symmetrically enlarged CSA in proximal segments and lower limbs on ultrasound.165 Finally, CMT2 is a heterogenous collection of variably inherited axonal polyneuropathies, with similarly variable findings on ultrasound.100,166

Research into nerve ultrasound as a longitudinal biomarker in CMT has been limited to date. A small study of 15 adults with CMT1A over 5 years failed to demonstrate a change in nerve calibre when assessing the sural and median nerves.167

Although outside the scope of this review, muscle ultrasound in a cohort with CMT has demonstrated reduced thickness and increased echointensity of the first dorsal interossei and tibialis anterior muscles.168 This was more pronounced in CMT1A compared to CMTX1 and CMT2A patients, and correlate with degree of muscle weakness. Consequently, nerve and possibly muscle ultrasound can improve diagnosis and assessments of severity in CMT.

HNPP is caused by an autosomal recessive deletion of the PMP22 gene, leading to multiple painless entrapment mononeuropathies. The classical ultrasound finding in HNPP is multiple areas of nerve enlargement at entrapment sites,169,170 but enlargement at non entrapment sites have also been described.171 Sonographic findings such as CSA do not correlate with neurophysiological parameters, such as the distal motor latency.172

Variant or hereditary transthyretin amyloidosis is an autosomal dominant disorder, where point mutations in the transthyretin gene results in an axonal sensorimotor and autonomic neuropathy. The recent development of disease modifying therapy has prompted great interest in diagnostic and treatment biomarkers. Ultrasound studies in vATTR Amyloidosis have reported increased nerve CSA at entrapment sites, proximal nerve segments and the brachial plexus when compared to healthy controls.100,173 CSA is also greater in symptomatic vATTR then asymptomatic carriers100 and in those with abnormal motor conduction studies.174 While carpal tunnel syndrome is common in vATTR, the median nerve CSA at the wrist is smaller than in idiopathic CTS and is discordant with EDX severity.175 This has been suggested as an early clinical clue for vATTR in patients presenting with CTS.

CANVAS is an adult-onset disorder caused by mutation in the RFC1 gene. A sensory neuronopathy is universally seen in patients with CANVAS,176 and can be detected on ultrasound as a reduction in CSA of the median, ulnar, tibial, and sural nerves.177 A reduced median and ulnar nerve CSA < 5 mm2 in the mid-forearm or mid-humerus demonstrate a sensitivity of 7993%, specificity 100% and area under the curve (AUC) of 0.970.99178 for distinguishing CANVAS from healthy controls.

SCA 2 is an autosomal dominant CAG triplet repeat mutation in the Ataxin 2 gene, resulting in cerebellar ataxia, sensory motor neuropathy, pyramidal and extrapyramidal dysfunction.179 Reduced nerve CSA on ultrasound is seen in the majority (74%) of patients and correlates with the presence of a sensory neuronopathy.177

Friedrich Ataxia is an autosomal dominant GAA triplet repeat disorder affecting the Frataxin gene, leading to cerebellar ataxia, cardiomyopathy and sensory neuropathy/neuronopathy. Interestingly, upper limb nerve CSA is enlarged in Friedrich ataxia, attributed to dysmyelintation and perineurial connective tissue proliferation,180 while lower limb nerve CSA is normal.

The utility of ultrasound in axonal PN is less well characterised. It was hypothesized initially that nerve calibre would be reduced in axonal neuropathies. However, ultrasound has revealed that nerves are typically either normal or slightly enlarged.23,119 The potential application of nerve ultrasound to many forms of axonal neuropathy, eg, toxic, metabolic, inflammatory aetiology remains to be defined by future research.

DPN is characterised sonographically by mild hypoechoic nerve enlargement, notably at compression sites. Several studies have reported enlarged CSA for the median and tibial nerves of Type 1 and Type 2 Diabetics with PN when compared to healthy controls.181184 Nerve enlargement can also predate clinical neuropathy,185 and increases further once DPN develops.186 In addition, the degree of enlargement and vascularity are biomarkers of severity, and correlate with clinical and EDX parameters.182,184,185 Further, in type 2 diabetics nerve ultrasound can demonstrate enlarged fascicles and marked hypoechogenicity when compared to controls, and this to correlates with EDX abnormalities.184,185 Type 2 diabetics with metabolic syndrome also demonstrate larger nerves and more severe neuropathy then diabetics without metabolic syndrome.187 Furthermore, increased tibial nerve stiffness on shear wave elastography is 90% sensitive and 85% specific for diabetes and increases with the development of DPN.188

Chemotherapy-associated PN demonstrates mild, often asymptomatic nerve enlargement at compression sites in 69% of patients and may point to nerve vulnerability to mechanical stress.188 In contrast, Lycan et al studied 20 patients with breast cancer exposed to taxane-based chemotherapy and reported reduced sural nerve calibre on ultrasound.190 Nerve size was further correlated with older age, longer time since exposure and intraepidermal nerve fibre density on skin biopsy.

Leprosy secondary to infection with Mycobacterium leprae is a prevalent cause for PN outside the western world191 and has been well studied with peripheral nerve ultrasound. Leprosy is characterised by both axonal and segmentally demyelinating PN with palpably thickened nerves and skin changes. Leprosy typically manifests with recurrent immune reactions referred to as active leprosy. Ultrasound studies have reported multiple asymmetric nerve enlargement with epineurial thickening.32,192195 Active leprosy is associated with nerve hypervascularisation in 5571% of patients and decreases to 2.75.9% with treatment.193,195 Thus, peripheral nerve ultrasound has potential as both a diagnostic and monitoring tool in Leprosy.193

EDX in children is challenging. EDX testing is potentially painful, with pain more frequently experienced when EMG is performed, when greater than one muscle and proximal muscles are tested.196 It is unsurprising therefore that younger age, especially under 3 years, is associated with inadequate and incomplete EDX in paediatric cohorts.196 Furthermore, EMG relies on active muscle recruitment and patient participation which is limited in the very young.197 Nerve imaging with MRI in children is also challenging due to the need to lie still for prolonged periods which may necessitate sedation. Nerve ultrasound on the other hand is painless, quick, adaptable, cost effective and well tolerated in paediatric patients.198 It seems natural therefore to see a recent growth in paediatric neuromuscular ultrasound research.107,199

Peripheral nerves increase in size as we age, meaning children with enlarged nerves may be incorrectly interpreted as normal if adult references values are applied. Therefore, the accurate interpretation of abnormal nerve CSA is reliant on the ongoing expansion age-specific normative ultrasound data.200,201 Zaidman et al23 examined 40 healthy children aged 217, among a larger cohort of 90 adults and children, and reported a range of normal CSA values. Of interest, an association between height and nerve CSA was seen, and was stronger in children (r =0.9, P < 0.001) than adults (r = 0.5, P < 0.001). Cartwright et al202 recorded peripheral nerve CSA in a further 43 children aged 3 months to 16 years as well 160 adults. Age was the strongest predictor of nerve CSA, although height and BMI were also predictive. Druzhinin et al201 systematically collected ultrasound CSA measurements in an children and young adults, scanning 72 healthy subjects aged 230 years. Their data suggest that nerve CSA is independently associated with age and weight but not height, differing from previous studies by Zaidman23 and Cartwright.201 Zaidman and Cartwright analysed for associations using pooled CSA values from all nerve measurements while Druzhinin analysed each nerve measurement individually, and this may explain their different findings. All three studies found nerve size plateaued at 1214 years leading the authors to conclude that paediatric specific normative values are essential to interpret imaging in subjects below this cut off. The intra and inter-nerve variability was measured in Zaidman and Druzhinins populations and interestingly did not differ significantly with age.23,201 This may be a potential age-independent measure to use where normative data is limited.

Entrapment mononeuropathies are uncommon in children, and when they do occur ultrasound can detect unusual causes such as mucopolysaccharidosis.203,204 Research in adult populations has been used to argue for supplementation or even replacement of standard EDX assessments with neuromuscular ultrasound in certain focal mononeuropathies such as carpal tunnel syndrome.46,205,206 A similar argument could be made for children with mononeuropathies but will require further studies to evaluate.

Polyneuropathies on the other hand are common in children and sonographic nerve changes are detectable in certain hereditary neuropathies such as CMT from a very young age.107,161 Further, nerve CSA in children with CMT1A correlates with disease severity, as well as age, height and weight.161 Furthermore, ultrasound can aid in the distinction between hereditary and acquired inflammatory polyneuropathies in this age group.107,119 Zaidman et al performed nerve ultrasound in 128 adults and children with a range of hereditary and acquired peripheral neuropathies. Thirty-five CMT1 patients age 271 years were examined and 8 out of 9 children with CMT demonstrated diffuse sonographic nerve enlargement.

Ultrasound has also been used to assess neonatal brachial plexopathy, which occurs in up to 3 in 1000 live births.207 The current standard is a 3-month period of observation for spontaneous recovery followed by surgical exploration where recovery is poor.208 In 2015, Somashekar et all compared preoperative US to surgical exploration in the detection of traction neuromas in 33 children.209 Of their cohort, 31 of the 33 surgically identified neuromas were detectable on US. Furthermore, muscle atrophy was identified in 11 children and guided spinal accessory and supra scapular nerve transfers in 8 of those patients.

Another advantage of ultrasound is its potential to limit the amount of EDX testing required to achieve a diagnosis. Rardin et al210 compared retrospective data from 21 children who were assessed by ultrasound prior to EDX with 84 aged-matched control subjects who had EDX assessment alone. Those subjects investigated with ultrasound first required less EDX tests, with fewer nerve stimulations and fewer muscles sampled by EMG. This led the authors to conclude an ultrasound first approach should be considered in paediatric patients to limit EDX testing.

Therefore, ultrasound has a number of distinct advantages in paediatric neuromuscular assessment and its role is likely to grow in this population. Further studies are needed to better define normal nerve size, as well as more detailed structural assessment such as fascicle measurements, echotexture and elastography.

Disorders of the motor neuron include Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and Spinal Bulbar Muscular Atrophy (SBMA or Kennedys disease) and Poliomyelitis. Diagnostic delay is a significant issue in these disorders, for instance in ALS the median time to diagnosis is 11.5 months after onset of symptoms.210 In SMA, the emergence of disease modifying therapy has generated the need for accessible, accurate, responsive, and reliable outcome measures. Hence, ultrasound has clear potential to improve the diagnosis and monitoring of motor neuron disease, and there is a growing body of literature supporting its use in ALS and SMA.

ALS is a fatal neurodegenerative disorder affecting the motor neuron, with a median survival of 35 years,212214 characterised by dysfunction of both upper and lower motor neurons (UMN and LMN) as well as cognition.213 Clinical heterogeneity exists, and there is an absence of pathognomonic investigations, leading to significant diagnostic delay.215 To better define the investigations of ALS and to promote recruitment of patients to clinical trials, the El Escorial and revised El Escorial (rEEC) were developed incorporating the presence of upper (UMN) and lower motor neuron (LMN) signs.216218 It was argued that the rEEC, although specific, was lacking in sensitivity, particularly in the early stages of disease, and consequently the Awaji criteria and more recently the Gold Coast criteria were developed.220224 These included the identification of fasciculations on EMG as an LMN sign and have contributed to the increased sensitivity in diagnosing ALS.216,224226 Neuromuscular ultrasound offers greater sensitivity then EMG in the detection of fasciculations especially in bulbar structures and thus has the potential to further improve the diagnostic sensitivity of the criteria.228 Further, muscle ultrasound in ALS can improve diagnosis through the detection of reduced muscle thickness and increased muscle echointensity98,227229 (Figure 7). Furthermore, quantitative measures of muscle echotexture have been used as diagnostic biomarkers and responsive outcome measures in ALS.230,231

Figure 7 Cross-sectional image of a normal tibialis anterior muscle (A) and quadriceps muscles (C) in a healthy individual. Cross-sectional image of abnormal tibialis anterior muscle (B) and vastus intermedius muscle and to a lesser extent rectus femoris muscle (D) in a person with amyotrophic lateral sclerosis. Note in the abnormal muscles there is atrophy with increased brightness or echointensity with a loss of the underlying bone reflection (*).

A reduction in motor nerve and cervical nerve root calibre with a sparing of sensory nerves has been consistently described in ALS232235 and is likely to reflect motor axon loss. This occurs in both clinically affected and unaffected regions.233 Nerve ultrasound can distinguish ALS from mimic disorders such as MMN and peripheral nerve hyperexcitability syndromes.236 Specifically an increased distal:proximal CSA ratio of the median nerve can distinguish ALS and reflects the relative density of motor fibres in the proximal portion of the nerve.236 Additionally, nerve ultrasound is abnormal in preclinical ALS where axonal degeneration is compensated and thus muscle wasting/weakness not yet apparent.233,237 Detecting the submillimetre nerve CSA changes in this preclinical state will likely improve as higher frequency ultrasound probes are developed and in wider use.237,238 One current limitation of nerve ultrasound is its insensitivity as a tool to monitor disease progression.238 Furthermore, nerve ultrasound measurements are not consistently correlated with disease severity on clinical and EDX measures, in part due to the confounding effect of UMN dysfunction.235

Bulbar motor neuron dysfunction, associated with dysphagia, is common in ALS, and can be measured by ultrasound in several ways. Video ultrasonography, a technique to dynamically assess tongue position and morphotexture during attempted swallow, is an early and sensitive measure of dysphagia in ALS.239 Further, ultrasound measures of tongue thickness are reduced in ALS, and this is most marked in those patients with bulbar onset disease and lower BMI.240 Furthermore, tongue thickness decreases with disease progression and may be used to monitor dysphagia and potentially guide timing of nutritional interventions such as parenteral feeding which are associated with improved survival in ALS.241,242 Lastly, minimal change in tongue thickness during swallowing, measured as a reduced thickness ratio is a specific marker of UMN bulbar dysfunction.243 Thus, dynamic tongue ultrasound has potential as a diagnostic and prognostic biomarker of bulbar dysfunction in ALS.

Respiratory dysfunction is universal in ALS as the disease progresses.244 Monitoring respiratory dysfunction, traditionally with spirometry, is essential to guide institution of non-invasive ventilation which can improve survival and quality of life.244246 A major limitation of spirometry in ALS is its poor reliability in the setting of bulbar and facial weakness as well as cognitive impairment. Dynamic diaphragmatic ultrasound thickness, measured as inspiration:expiration thickness or thickening ratio, offers an alternative measure in such patients. Ultrasound diaphragm thickness and thickening ratio are reliable in ALS,247 and correlate with vital capacity, hypercapnia, hypoventilation and motor disability more broadly.247 Thus, diaphragmatic ultrasound represents an important diagnostic biomarker for respiratory dysfunction in ALS,248 although at this stage it remains experimental and is not a substitute for standard measurements.

SMA is an autosomal recessive disorder of spinal lower motor neurons, caused by the mutation in the survival motor neuron (SMN1) gene. This ranges in severity from the severe type 1 SMA with onset before 6 months of age to Type 4 SMA with adult onset. There is considerable interest in biomarkers for diagnosis and disease progression in SMA due to the emergence of disease modifying therapy in the form of antisense oligonucleotides (Nusinersen and Risdiplan) and the gene replacement therapy (onasemnogene abeparvovec-xioi). Nerve ultrasound can distinguish adult onset SMA from mimicking disorders such as CIDP and MMNCB, based on reduced proximal nerve and nerve root CSA in SMA.249

In addition, high-frequency nerve ultrasound may provide prognostic information. This was suggested in a pilot study of 3 SMA patients using ultra high-frequency median nerve imaging.250 A reduced median nerve CSA and fascicle number was seen in the most severely affected subject (SMA I) relative to controls. Further, quantitative muscle ultrasound echo intensity, expressed as a Luminosity ratio, was increased in a cohort of SMA II and III subjects compared to healthy controls.251 Luminosity ratio was higher in more severe disease (SMA II) and correlated with dynamometry measures of strength. This suggests the diagnostic and monitoring potential for muscle ultrasound in SMA. Further research is needed to assess the role of nerve and muscle ultrasound in SMA.

The use of ultrasound to assess peripheral nerves in routine clinical practice is increasing due to its safety, accessibility, and dynamic quality. Current ultrasound technology provides excellent resolution of peripheral nerves and the flexibility of point of care machines allow easy integration into neuromuscular and electrodiagnostic clinics. Ultrasound adds critical structural information to compliment clinical and EDX assessments, contributing to improved diagnosis and pathophysiological understanding of peripheral nerve disorders. While nerve ultrasound is most frequently used to diagnose focal compressive mononeuropathy, its application has grown to include traumatic nerve injury, generalised peripheral neuropathy, motor neuron diseases and a range of other neuromuscular conditions in both adult and paediatric populations. Despite the operator-dependant nature of ultrasound, further development of quantitative measures, standardised protocols and consensus scoring frameworks will allow wider application and lead to improved diagnosis of peripheral nerve disease.

Funding support from the National Health and Medical Research Council of Australia is gratefully acknowledged.

Professor Matthew C Kiernan reports grants from NHMRC, is the Editor-in-Chief of Journal of Neurology, Neurosurgery & Psychiatry, during the conduct of the study. The authors report no conflicts of interest in this work. There are no financial interests or other conflicts of interest to declare.

1. Latinovic R, Gulliford MC, Hughes RA. Incidence of common compressive neuropathies in primary care. J Neurol Neurosurg Psychiatry. 2006;77(2):263265. doi:10.1136/jnnp.2005.066696

2. Hulkkonen S, Lampainen K, Auvinen J, Miettunen J, Karppinen J, Ryhnen J. Incidence and operations of median, ulnar and radial entrapment neuropathies in Finland: a nationwide register study. J Hand Surg Eur Vol. 2020;45(3):226230. doi:10.1177/1753193419886741

3. Musolin K, Ramsey JG, Wassell JT, Hard DL. Prevalence of carpal tunnel syndrome among employees at a poultry processing plant. Appl Ergon. 2014;45(6):13771383. doi:10.1016/j.apergo.2014.03.005

4. Musolin KM, Ramsey JG. Carpal tunnel syndrome prevalence: an evaluation of workers at a raw poultry processing plant. Int J Occup Environ Health. 2017;23(4):282290. doi:10.1080/10773525.2018.1474420

5. Gonzalez NL, Hobson-Webb LD. Neuromuscular ultrasound in clinical practice: a review. Clin Neurophysiol Pract. 2019;4:148163. doi:10.1016/j.cnp.2019.04.006

6. Jablecki CK, Andary MT, Floeter MK, et al. Practice parameter: electrodiagnostic studies in carpal tunnel syndrome. Report of the American Association of Electrodiagnostic Medicine, American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2002;58(11):15891592. doi:10.1212/wnl.58.11.1589

7. Boonyapisit K, Katirji B, Shapiro BE, Preston DC. Lumbrical and interossei recording in severe carpal tunnel syndrome. Muscle Nerve. 2002;25(1):102105. doi:10.1002/mus.10002

8. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123(Pt 4):665676. doi:10.1093/brain/123.4.665

9. Simmons Z, Feldman EL. Update on diabetic neuropathy. Curr Opin Neurol. 2002;15(5):595603. doi:10.1097/00019052-200210000-00010

10. Kandula T, Farrar MA, Cohn RJ, et al. Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: clinical, neurophysiological, functional, and patient-reported outcomes. JAMA Neurol. 2018;75(8):980988. doi:10.1001/jamaneurol.2018.0963

See the original post here:
Spotlight on ultrasonography in the diagnosis of PND | IJGM - Dove Medical Press

Read More...

Eye scan could determine whether COVID patients will be long haulers – WGNO New Orleans

August 17th, 2021 1:49 am

(StudyFinds.org) Long COVID continues to confound doctors as patients still struggle with debilitating symptoms months after first being infected. A new study now suggests that COVID patients who could be long-haulers could be diagnosed by taking a close look at their eyes. Nerve fiber loss and an increase in key immune cells on the surface of the eye may be a way of identifying the long term impact of the virus, say scientists.

The changes are particularly evident among those with neurological symptoms, such asloss of taste and smell,headache, dizziness, numbness, and neuropathic pain. Doctors at Weill Cornell Medicine-Qatar say long COVID ischaracterized by a range of symptomswhich continue for more than four weeks after the acute phase of the infection has passed, and which arent explained by an alternative diagnosis.

CCM has been used to identify nerve damage and inflammatory changes attributable to diabetic neuropathy,multiple sclerosis, and fibromyalgia..

Forty people who had recovered from confirmed COVID-19 infection between one and six months earlier completed a National Institute of Health and Clinical Excellence (NICE) questionnaire. Data was used to find out if they had long Covid, with a total score ranging from zero to 28. Neurological symptoms were present at four and 12 weeks in 22 out of 40 patients (55 percent) and 13 out of 29 (45 percent), respectively, according to the findings published in theBritish Journal of Ophthalmology.

The participants corneas were then scanned using CCM to look for small nerve fiber damage and the density of dendritic cells. These have a key role in the primaryimmune system responseby capturing and presenting antigens from invading organisms.

The corneal scans were compared with those of 30 healthy people who hadnt been infected by COVID.

Results show that 55 percent of theCOVID patientshad no clinical signs of pneumonia. Twenty-eight percent had clinical signs of pneumonia not requiring oxygen therapy. Ten percent had been admitted to hospital with pneumonia and received oxygen therapy, and 8 percentt with pneumonia had been admitted to the intensive care.

The corneal scans revealed that patients with neurological symptoms for four weeks after they had recovered from acute COVID-19 had greater corneal nerve fiber damage and loss, with higher numbers of dendritic cells, than those who hadnt been infected by the virus. Those without neurological symptoms had comparable numbers of corneal nerve fibers as those who hadnt been infected with COVID, but higher numbers of dendritic cells.

The questionnaire responses indicative oflong COVID symptomscorrelated strongly with corneal nerve fiber loss, says study author Professor Rayaz Malik in astatement.

He notes that it was an observational study, and as such, cant establish cause, and only a small number of participants were involved.

To the best of our knowledge, this is the first study reporting corneal nerve loss and an increase in [dendritic cell] densityin patients who have recoveredfrom COVID-19, especially in subjects with persisting symptoms consistent with long COVID, he adds. We show that patients with long COVID have evidence of small nerve fiber damage which relates to the severity of long COVID and neuropathic as well as musculoskeletal symptoms. Corneal confocal microscopy may have clinical utility as a rapid objective ophthalmic test to evaluate patients with long COVID.

South West News Service writer Stephen Beech contributed to this report.

Continue reading here:
Eye scan could determine whether COVID patients will be long haulers - WGNO New Orleans

Read More...

Diabetic Neuropathy Treatment Market Trends and Forecast to 2027 Players are Abbott, Roche, Eli Lilly – The Manomet Current

August 17th, 2021 1:49 am

The Diabetic Neuropathy Treatment Market is expected to account for a robust CAGR of 5.6% during the forecast period of 2021-27. The market held a CAGR of xx % in 2021 and xx USD billion in terms of revenue.

Once the immediate and direct impact of COVID-19 has passed in a given geographic area, the consequences of delaying care will almost certainly generate new issues for individuals and the healthcare system, potentially raising annual expenses globally. The pandemic has created an everlasting impact on the market and the healthcare industry.

The scope of our market report is to provide you with top-notch information on the market. The report consists of pie diagrams, bar diagrams, line diagrams, and other infographics to give a holistic and scrutinized view of the dynamic environment of the market. This reports analysis aids players in the business in comprehending shifting market dynamics through time.

Get a Sample Copy of the Report to understand the structure of the complete report

https://www.oneupbusinessinsights.com/request_sample.php?tname=311083

Top key players: Abbott, Roche, Eli Lilly, Johnson and Johnson, GlaxoSmithKline, Lupin, Glenmark, Depomed, Astellas, and Pfizer

Segmentation of Diabetic Neuropathy Treatment Market:

Product Type Coverage

Peripheral Neuropathy

Autonomic Neuropathy

Proximal Neuropathy

Focal Neuropathy

Application Coverage

Hospitals

Clinics

Others

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Diabetic Neuropathy Treatment Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Diabetic Neuropathy Treatment Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Diabetic Neuropathy Treatment Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:What will the market size and the growth rate be in 2027?What are the key factors driving the Diabetic Neuropathy Treatment Market?What are the key market trends impacting the growth of the Diabetic Neuropathy Treatment Market?What are the challenges to market growth?Who are the key vendors in the Diabetic Neuropathy Treatment Market?What are the market opportunities and threats faced by the vendors in the Diabetic Neuropathy Treatment Market?Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

More Information:

The report includes six parts, dealing with:1.) Basic information;2.) The Asia Diabetic Neuropathy Treatment Market;3.) The North American Diabetic Neuropathy Treatment Market;4.) The European Diabetic Neuropathy Treatment Market;5.) Market entry and investment feasibility;6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before ONE UP Business Insights curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.Diabetic Neuropathy Treatment Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Get Up to 20% Discount on this Premium Report https://www.oneupbusinessinsights.com/request_sample.php?tname=311083

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Statistical surveying reports are a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Vick Batho(Assistant Manager Business Development)

US: +1 315 675 7779

3811 Ditmars Blvd, Astoria, NY-1115

sales@oneupbusinessinsights.com

http://oneupbusinessinsights.com/

Read the original post:
Diabetic Neuropathy Treatment Market Trends and Forecast to 2027 Players are Abbott, Roche, Eli Lilly - The Manomet Current

Read More...

The Feather and the Knife: Navigating Life With Chronic Pain – POZ

August 17th, 2021 1:49 am

For Jess Guilln, pain is a feather touch and a constant companion. To illustrate, Guilln, who has been living with HIV since 1985, moves one elegant hand, bending at the wrist to mimic running a feather gently along skin.

I just start doing this over and over and over, he says. I tell people, This is a feather. But what do you feel if I keep doing this for 30 minutes, or for an hour?

Usually, folks push him away, irritated at the sensation. Thats one of the ways Guilln describes the chronic pain that sometimes keeps him in bed until noon and can make every step hurt. But thats not the only way he describes it. Theres the feeling of a nail or a thorn from a rose pressed nonstop against skin. And then, theres the pain that wakes him up in the middle of the night and consumes his thoughts, like a knife stabbing him over and over again. For Guilln, chronic pain is a lack of sensation, then, all at once, too much sensationand a sensation he cant escape.

It never stops. [People with chronic pain] dont get used to it, but we manage somehow, he says. We still want to experience life in some way.

Guilln is far from alone. Studies have found that between 25% and 85% of people living with HIV experience chronic pain, compared with estimates of 11% to 20% of the general population. Often, this is neuropathic painpain that starts in the brain but is usually experienced as numbness, tingling, burning or stabbing in the limbs, hands and feet.

Despite the high rates of pain, some research suggests that people living with HIV are less likely to be prescribed opioid pain treatment than their HIV-negative peers. The additional challenge of coexisting substance use disorders can render even that form of pain relief elusive for some people with HIV. But the opioid epidemic has led to new research on pain and how to address it at its core, including specifically for people living with HIV.

What We Know About Pain and HIV

Jessica Robinson-Papp, MD, had just come off a general medicine internship at St. Vincents hospital in New York City, where she fell in love with working with HIV-positive people, when she began training in neurology. Luckily for her, she was able to combine her passions. Today, shes a clinical neurologist at New York Citys Mount Sinai Hospital, serving people with HIV who have a variety of pain syndromes.

The more people with HIV she saw, the more Robinson-Papp realized that peripheral neuropathy was usually just one of a litany of pain complaints her patients had.

Youll start talking about neuropathic pain, she says. And then theyll say, Oh, but then, theres back pain, and Theres pain radiating down, and Theres pain over here, and Then, there are headaches.

What shes learned, and what the science of pain in general has revealed, is that there is no one cause of pain, or, if there is, science hasnt discovered it yet. Its not even clear whether people living with HIV really experience more pain than people without HIV, Robinson-Papp says.

We dont even really know that, she says. Understanding the [source] of pain is very much in its infancy.

We manage somehow. We still want to experience life.

What researchers do know is that pain is more likely a syndromea constellation of symptomsthan one disease with a single cause that can be cured. In fact, each kind of pain could have a different cause.

For instance, neuropathy is often a side effect of older HIV medications or chemotherapy for AIDS-defining illnesses. It could also be due to accelerated aging in people with HIV. Then theres degenerative joint diseasethat is, joint pain due to osteoarthritis or avascular necrosis, which often necessitate joint replacements. For people who menstruate, menopause can come with its own kinds of pain. HIV-associated chronic inflammation is another likely contributor to pain, Robinson-Papp says.

Whats more, people with one pain syndrome, such as HIV-associated peripheral neuropathy, are more likely to have another, like migraines or joint pain from osteoarthritisor even multiple other pain syndromes. Scientists dont know why that is either, says Robinson-Papp.

Plus, some factors may amplify ones perception of pain. For instance, its possible that some HIV viral proteins themselves may enhance pain. Pain is also associated with other health conditions, such as depression, anxiety or posttraumatic stress disorder, most of which can be part of whats known as AIDS Survivor Syndrome, a cluster of symptoms resulting from trauma endured during the early years of the epidemic.

Then there are factors that can make it easier to focus on pain, like the social isolation that can accompany aging. Moreover, certain behaviors, such as lack of exercise, can increase pain, and conditions such as insomnia or drug misuse or addiction (which can be an attempt to self-medicate) can complicate how individuals cope with pain.

All of this can impact the ability to take HIV meds as prescribed, which can deprive people with uncontrolled pain of the health benefits of having an undetectable viral load.

So when Robinson-Papp talks to patients about options to alleviate pain, the first step is to see if theres a physical reason for it, like diabetes, autoimmune diseases, infections such as hepatitis B or C or malnutrition associated with alcoholism.

But once Robinson-Papp has helped patients address those problems, there are only a few proven solutions she can offer people to help manage their pain or at least cope with it. These include physical therapy, massage, acupuncture, mindfulness-based stress reduction, cognitive behavioral therapy, exercise, non-opioid pain relievers and cortisone injections (for joint pain). Some data show that cannabis and capsaicin (derived from chili peppers) alleviated some pain in people with HIV, according to a systematic review published in a recent special issue of the journal AIDS Care on the topic of HIV and chronic pain that Robinson-Papp coedited. But the quality of the data were low, and more work is needed to confirm their effectiveness, researchers wrote.

That leaves one last option. Sometimes people are on opioids, she says. Thats a fact of life.

Guilln knows this all too well. Its taken years to find the right mix of meds, one that keeps the pain to a manageable level but doesnt wallop him with brain fog or fatigue. He rattles off the list of meds hes tried for pain: Cymbalta, morphine, medicines for depression, even schizophrenia drugs.

For five years, hes been on a regimen that works for him: a base of 20 milligrams of OxyContin (oxycodone hydrochloride) twice a day, with Norco (a combination of hydrocodone and acetaminophen) as needed but no more than one pill every four hours. He augments these with over-the-counter pain patches, hot and cold compresses, a device to deliver nerve stimulation to muscles and massagers.

Temperature, movement, vibrationthese are all different elements that affect whatever youre feeling, he says. But this is not a formula or a recipe. It is a lot of work, sadly, to find whatever works for you.

Opioid Epidemic Leads to Innovations

Sciences understanding of HIV and pain may be about to change, however. In the HIV and chronic pain issue of AIDS Care, a global task force of HIV experts began to lay out a research agenda for studying pain in people with HIV. (Their preference: Start with what causes it.) The issue includes new data showing that many HIV-positive people cant separate their chronic pain from their experience of having the virus.

The HIV Global Pain Task Force, of which Robinson-Papp is a member, is now soliciting recommendations for the HIV pain research agenda from people living with HIV.

Another effort is more wide-ranging. The National Institutes of Health (NIH) launched the Helping to End Addiction Long-term (HEAL) Initiative in 2018 and has so far funded it with $1.5 billion to back experimental research and the development of medical devices that might treat opioid use disorder or address or prevent pain.

The funding also supports the Pain Management Effectiveness Research Network, which is testing existing non-opioid drugs against pain, and the Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing as well as new research paths for interventions that could treat pain without requiring opioids.

Thats where Marco Loggia, PhD, associate director of Massachusetts General Hospitals Center for Integrative Pain NeuroImaging, comes in.

Loggia isnt an HIV researcher. But he has dedicated his career to studying what pain of all sorts looks like in the brain using PET and MRI scans.

Neuroinflammation is what brought him to HIV. Chronic HIV infection can lead to persistent immune activation and inflammation even among people on effective antiretroviral treatment who have an undetectable viral load.

Loggias lab was the first to show that in people with chronic pain a protein in the brain called translocator protein (TSPO) is present in unusually high numbers in the thalamus, the part of the brain that perceives pain and other stimuli. If his theory is correct and the presence of TSPO in people with chronic pain isnt just a coincidence but actually an objective marker of how much pain people are in, lowering TSPO might also reduce how much pain a person feels, without the need for opioids. Drugmakers could then develop medications that target and reduce TSPO and therefore reduce the pain itself.

HIV is a perfect storm of neuroinflammation, he says. We wanted to knowabove and beyond the inflammation associated with the viruswhy some people with HIV have pain and some dont.

In short, if all people with HIV have neuroinflammation, why dont they all also have pain? And does neuroinflammation look different in the brains of HIV-positive and HIV-negative people with chronic pain?

Loggias current study is recruiting participants in the Boston area to be part of an imaging study to look at just this. It divides participants into three categories: 30 people living with HIV without chronic pain, 30 people with HIV and chronic pain who engaged in opioid pain management and 30 people with HIV with chronic pain not taking opioids. Thats because of another complication of opioid use: Scientists think ongoing opioid use could actually increase inflammation, and maybe TSPO, in the brain.

The HEAL Initiative gives Robinson-Papp hope for the future of pain treatment for people living with HIV.

The HEAL Initiative has really brought together the addiction world and the pain world, which I think is extraordinarily beneficial, particularly for the pain world, because there are ways addiction medicine conceptualizes care that would be really lovely for us as well, she says, noting addiction cares focus on harm reduction. You have to think about the whole personwhere they live, what the context of their pain is.

Jess GuillnAngela DeCenzo

Reclaiming Joy

One of Guillns early memories as a child was dancing with his aunts. One aunt would take him by the hand, and another aunt would grab his sister. They would teach the kids salsa and other dances. When Guilln remembers it, he beams with adoration for his aunts, one of whom recently died.

In the years since, his experience in his body is, like pain, never just one thing. The breathtaking rush of a first kiss and first touch with another man linger with memories of the burning under his skin that came with his HIV diagnosis. The horror of the feel of bald patches on his scalp from the stress of being closeted and living with HIV in 1985 coexist with the youthful energy of nights spent at discos, dancing until dawn. Theres the mix of adrenaline and the great vibration in his chest from standing in front of a crowd and singing. Now, at 60, in chronic pain and with a hip replacement, Guilln is proud of the fact that these days, when he does dance, he can still break it down all the way to the ground.

Sometimes, when every step on the sidewalk feels like stabbing, he imagines hes walking on a bed of Jell-O. It takes him out of his current body, this painful body that nevertheless he loves.

He can still access the joy he felt dancing as a child. It will cost him in energy and recovery later, but for five or 10 minutes, his feet move in that familiar way, in concert with his shoulders, hips leading, weight shifting from balls of feet to heels, shoulders shifting to compensate. For those minutes, he is that child again, dancing in the kitchen with his aunt.

Some days, thats just a fantasy. But he can escape into that memory and know what its been like to be a whole person in a currently painful body.

Even if were sitting down, we can have those wonderful memories of movement, he says, as his hands come up in front of his chest and his shoulders shimmy. And even with just the hands, or the hands right here, we are in our brains really doing the twist. And it might help.

Read more:
The Feather and the Knife: Navigating Life With Chronic Pain - POZ

Read More...

Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing – Yahoo Finance

August 17th, 2021 1:49 am

Financing strengthens balance sheet, furthers financial and operational flexibility and lowers overall cost of capital

No financial covenants and no warrants issued in connection with non-dilutive financing

Full drawdown expected to extend cash runway to support key value-creating milestones including availability of Phase 1/2 GAN data from the highest dose cohort as well as regulatory guidance on registration pathway for GAN, data readouts in GM2 gangliosidosis, Rett syndrome, CLN1 disease, and SURF1-associated Leigh syndrome and, importantly, a potential regulatory approval for TSHA-120 in GAN without the need for additional financing

DALLAS, August 16, 2021--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that it has entered into a loan and security agreement with Silicon Valley Bank (SVB) that provides Taysha with up to $100 million of borrowing capacity.

"Access to this non-dilutive financing at an attractive cost of capital, along with the current cash on hand, will provide Taysha with operational and financial flexibility to achieve numerous value-generating milestones including a potential regulatory approval for TSHA-120 in giant axonal neuropathy, or GAN," said RA Session II, Chief Executive Officer of Taysha. "Additional milestones include the release of Phase 1/2 data in the highest dose cohort in GAN, and Phase 1/2 data in GM2 gangliosidosis, Rett syndrome, CLN1 disease and SURF1-associated Leigh syndrome. We are pleased to partner with SVB as we continue to execute on our ambitious business plan."

This non-dilutive financing provides Taysha with up to $100 million, with $40 million available at closing of which Taysha has drawn $30.0 million. The Company has the option to draw down the remaining tranches, subject to certain conditions. The interest rate is the greater of 7.0% or the WSJ Prime Rate plus 3.75%. There are no financial covenants and no warrants associated with the term loan.

Story continues

"Our financial commitment to Taysha speaks to our confidence in its core strategies and is consistent with our support of innovative life sciences businesses," said Michael White, Head of Business Development, Life Science & Healthcare, Silicon Valley Bank. "We are delighted to provide additional capital for the Company to further advance its robust development pipeline and achieve key value-generating milestones in the years to come."

"In the last 12 months, we have quickly made the transition from a private to public company and from preclinical to clinical to pivotal-stage," said Kamran Alam, Chief Financial Officer of Taysha. "Building upon this momentum, we expect this non-dilutive financing to enable us to be well positioned to maximize long-term stockholder value."

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platforman engine for potential new cureswith a goal of dramatically improving patients lives. More information is available at http://www.tayshagtx.com.

About Silicon Valley Bank

For nearly 40 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators. Learn more at svb.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the anticipated use of proceeds from borrowings under the loan and security agreement, our ability to access the full $100 million potentially available under the loan and security agreement and our ability to fund operations into the second half of 2023. Forward-looking statements are based on managements current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ("SEC") filings, including in our Annual Report on Form 10-K for the year ended December 31, 2020 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, both of which are available on the SECs website at http://www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005185/en/

Contacts

Company Contact: Kimberly Lee, D.O.SVP, Corporate Communications and Investor RelationsTaysha Gene Therapiesklee@tayshagtx.com

Media Contact: Carolyn HawleyCanale Communicationscarolyn.hawley@canalecomm.com

Read more here:
Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing - Yahoo Finance

Read More...

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update – Yahoo Finance

August 17th, 2021 1:49 am

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update

Expanded F H AB Intellectual Property Portfolio

Completed $15.9 million At-The-Market Financing

SON-1010 and SON-080 on track for IND submissions by calendar year end

PRINCETON, NJ / ACCESSWIRE / August 16, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30th , 2021 and provided a business update.

"Throughout the quarter, we've continued to make several advancements towards the clinic with our proprietary Fully Human Albumin Binding (F H AB) pipeline assets, and our partnered product" commented Pankaj Mohan, Ph.D., Founder and CEO. "We are progressing our SON-1010 (F H AB-IL12) and SON-080 (Low-dose IL-6) programs, with IND applications on track to be filed with the FDA for both before the end of 2021, with an additional IND for SON-1210 (IL12-F H AB-IL15) during the first half of 2022. We remain confident that the ability to deliver a therapeutic payload in a more targeted manner than traditional, wild-type cytokines has the potential to result in greater efficacy with an improved toxicity profile."

"We are pleased with our ongoing financing strategy, which is designed to provide the company with the funding necessary to advance our R&D activities and to grow the company beyond 2021," commented Jay Cross, CFO.

FY 2021 Third Quarter and Recent Corporate Updates

Sonnet provided the following corporate updates:

In May 2021, Sonnet entered into a license agreement with New Life Therapeutics, granting exclusive licenses to develop and commercialize SON-080 for the prevention, treatment, or palliation of diabetic peripheral neuropathy in certain territories in Asia.

In June 2021, the United States Patent and Trademark Office issued U.S. Patent No. 11,028,166 entitled "Albumin Domain Fusion Proteins" that covers Sonnet's F H AB technology. The patent also includes therapeutic fusion proteins that utilize F H AB for tumor targeting and retention, thereby providing extended pharmacokinetics.

Story continues

In June 2021, Sonnet executed its final issuance of shares of its common stock under the At-the-Market Sales Agreement, pursuant to which the Company executed issuances of an aggregate of 7,454,238 Shares for aggregate gross proceeds of $15,874,999.

FY 2021 Third Quarter Ended June 30, 2021 Financial Results

As of June 30, 2021, Sonnet had $6.0 million cash on hand.

Research and development expenses were $3.9 million for the three months ended June 30, 2021, compared to $2.5 million for the three months ended June 30, 2020. The increase of $1.4 million was primarily due to increased expenditures for the development of the cell line for IL12-FHAB and IL12-FHAB-IL15 and increased costs for research and development activities due to the acquisition of Relief and an increase in payroll and share-based compensation expense as operations are expanded.

General and administrative expenses were $2.4 million for the three months ended June 30, 2021, compared to $2.5 million for the three months ended June 30, 2020. The decrease of $0.1 million was primarily due to a $0.9 million decrease in professional fees and transaction-related fees associated with the closing of the merger, offset by an increase in payroll and share-based compensation expense of $0.7 million to support expanded operations.

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as F H AB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. F H AB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or the Company's financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Sonnet Biotherapeutics Investor Contact

Michael V. Morabito, Ph.D.Solebury Trout917-936-8430mmorabito@soleburytrout.com

Sonnet BioTherapeutics Holdings, Inc.Consolidated Balance Sheets(unaudited)

June 30,

September 30,

2021

2020

Assets

Current assets:

Cash

$

6,038,190

$

7,349,903

Prepaid expenses and other current assets

934,213

287,738

Total current assets

6,972,403

7,637,641

Property and equipment, net

58,644

67,889

Operating lease right-of-use asset

144,787

205,919

Other assets

-

82,959

Total assets

$

7,175,834

$

7,994,408

Liabilities and stockholders' equity

Current liabilities:

Related-party notes

$

748

$

21,184

Accounts payable

2,150,791

2,057,559

Accrued expenses

2,508,956

2,063,678

Operating lease liability

91,239

82,060

Deferred income

1,000,000

500,000

Total current liabilities

5,751,734

4,724,481

Note payable

-

124,878

Operating lease liability

55,464

125,132

Total liabilities

5,807,198

4,974,491

Stockholders' equity:

Preferred stock; $0.0001 par value: 5,000,000 shares authorized. No shares issued or outstanding

-

-

Common stock; $0.0001 par value: 125,000,000 shares authorized; 24,757,847 and 14,724,105 issued and outstanding at June 30, 2021 and September 30, 2020, respectively

2,475

1,472

Additional paid-in capital

56,103,306

39,723,702

Accumulated deficit

(54,737,145

)

Excerpt from:
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update - Yahoo Finance

Read More...

Ugly Side Effects of Too Many Vitamins – Eat This Not That – Eat This, Not That

August 17th, 2021 1:49 am

Most of us learn pretty earlywhether it's via an ice cream headache or pizza-party hangoverthat it is indeed possible to get too much of a good thing. Unfortunately, as health-conscious adults, many of us are slow to realize the same lesson still applies. When it comes to vitamins and supplements, more doesn't mean better. Taking too many vitamins can have unpleasant or serious side effects, and some vitamins shouldn't be taken in supplement form at all. Read on to find out moreand to ensure your health and the health of others, don't miss these Sure Signs You Have "Long" COVID and May Not Even Know It.

The first sign that you've taken too many vitamins or supplements is usually gastrointestinal. You might experience nausea, vomiting or diarrhea. It might mean you've taken a vitamin on an empty stomach that you'd better tolerate with foodor that you're taking more supplements than your body should handle. To be safe, it's always a good idea to talk with your doctor before beginning a new vitamin or supplement regimen.

This is one of the side effects associated with taking too much vitamin A, which is a fat-soluble vitamin. Unlike water-soluble vitaminsof which the body eliminates any excess in the urinefat-soluble vitamins are stored in body fat. If you take too many, that can result in toxicity. The other fat-soluble vitamins are D, E and K, and you should take care not to exceed the recommended daily dosage of each.

RELATED: What Taking a Vitamin Every Day Does to Your Body

Yikes. But indeed, that's what research has indicated about taking supplements of beta-carotene or vitamin E, or excessive amounts of biotin. Last spring, the United States Preventive Services Task Force (USPSTF) officially recommended against taking vitamin E or beta-carotene supplements, saying they may increase the risk of cancer or poor outcomes from heart disease. Another study found that men had an increased risk of lung cancer after taking megadoses of biotin (5 mg to 10 mg daily).

RELATED: The #1 Best Supplement to Take For Immunity

Taking too much of certain vitamins, such as vitamin B6, can result in nerve issues, such as neuropathy (numbness) or tingling. To avoid this, never take more than the recommended daily allowance.

RELATED: Signs You're Getting One of the "Most Deadly" Cancers

Another potentially dangerous vitamin or multivitamin ingredient is vitamin E. "Unless you have a reason to take vitamin E, you shouldn't be taking it as a random supplement," says Kathryn Boling, MD, a family medicine doctor with Mercy Medical Center in Baltimore. "We used to think it was good to take because it's an antioxidant, but it turns out the risk is higher than the benefit." That risk: Vitamin E thins the blood, which could turn minor injuries into serious bleeding episodes.And to get through this pandemic at your healthiest, don't miss these 35 Places You're Most Likely to Catch COVID.

Original post:
Ugly Side Effects of Too Many Vitamins - Eat This Not That - Eat This, Not That

Read More...

5 foods to avoid with arthritis to reduce pain

August 17th, 2021 1:48 am

Some people find that making changes to their diet improves their arthritis symptoms. This may involve avoiding inflammatory foods, such as saturated fat and sugar. It may also involve avoiding foods that are high in purines.

In this article, we look at five types of food a person with arthritis may benefit from avoiding, as well as foods that may help.

Read on to find out which foods to avoid with arthritis.

Several types of fat increase inflammation in the body. According to the Arthritis Foundation, a person with arthritis should limit:

One study in Nutrients indicates that people who drink regular sugar-sweetened soda have an increased risk of RA. Harvard Health note that excess sugar consumption also increases the risk of dying from heart disease. It can also lead to obesity, inflammation, and other chronic diseases.

Many products contain added sugars. Always check food labels on breakfast cereals, sauces, and soft drinks, as these may contain surprising amounts of added sugars.

AGEs are inflammatory compounds that can accumulate in tissues, particularly as someone ages. An article in Patient Education explains that people with diseases such as diabetes and RA often have increased AGE levels. So, reducing AGE levels may help reduce inflammation.

Fat and sugar both increase AGE levels in the body. Some food processing methods and high temperature cooking also increase the AGE levels in food.

Nightshades are a group of vegetables that contain the compound solanine. Studies have not confirmed that nightshades can trigger arthritis pain, but the Physicians Committee for Responsible Medicine indicate that removing them from the diet helps improve symptoms in some people.

Nightshade vegetables include:

The Arthritis Foundation advise that people who suspect nightshades might exacerbate symptoms exclude them from their diet for a couple of weeks, then reintroduce them one at a time.

Keeping a food diary may help a person keep track of any reactions they have to a specific food.

For people who have gout, a doctor may advise a low purine diet combined with the medication.

Purines are substances in foods that the body converts to uric acid. Uric acid can build up in the bloodstream, causing a gout attack. According to the Centers for Disease Control and Prevention (CDC), the following foods are high in purines:

However, a 2018 review identified that some purine-rich vegetables, such as cauliflower, mushrooms, and beans, have no links to gout risk.

There are several types of arthritis, all of which cause pain, swelling, and stiffness in the joints. The most common form of arthritis is osteoarthritis. Other forms include:

According to the Centers for Disease Control and Prevention (CDC), 23% of adults in the United States have a form of arthritis.

What a person eats can help:

Usually, inflammation protects the body from harm by helping defend against bacteria and aiding wound healing. However, when inflammation persists for an extended period, chronic symptoms can develop.

What a person eats has an impact on inflammation levels. Some foods are inflammatory, and others are anti-inflammatory.

According to the Arthritis Foundation, numerous studies show that anti-inflammatory foods can reduce arthritis pain and progression.

A persons body weight also influences inflammation levels. Fat cells produce cytokines, which are immune cells that increase inflammation.

A person can use diet to maintain a moderate weight, which may help with inflammation and also reduce pressure on the joints.

Finally, some types of arthritis have specific trigger foods. For example, foods that are high in purines can contribute to a gout attack.

Consuming the following foods may benefit people with arthritis.

The Arthritis Foundation list the following as types of fat that can reduce inflammation:

Coconut oil may also be beneficial for arthritis. Animal studies show that even though coconut oil is a saturated fat, it has anti-inflammatory properties. Researchers need to carry out more controlled studies to confirm this benefit in humans.

According to the Physicians Committee for Responsible Medicine, some studies indicate that plant-based diets can decrease RA symptoms. The Arthritis Foundation suggest that the following fruits and vegetables may be especially beneficial for people with arthritis:

Eating an anti-inflammatory diet can help someone stay healthy and avoid the symptoms of inflammation. One of the most researched anti-inflammatory diets is the Mediterranean diet.

The Mediterranean diet focuses on the following foods:

The diet also includes moderate levels of dairy products but limits sugar, alcohol, and red meat.

The Arthritis Foundation note that a Mediterranean diet can reduce inflammation and pain in people with osteoarthritis and protect against fracture risk.

Some people who follow the Mediterranean diet may also lose weight without counting calories or limiting portion sizes because the diet is predominantly plant-based.

A large population-based 2018 study found that men who followed the Mediterranean diet had a lower risk of developing RA. Another study suggests that the antioxidants in the Mediterranean diet may decrease pain for people with RA.

Other tips that may help someone to manage their arthritis include:

Foods that increase inflammation, such as sugar and saturated fat, may worsen arthritis symptoms. Some people may also find that foods high in purines and nightshades trigger arthritis flare-ups.

To identify triggers, a person can try excluding suspected foods for a couple of weeks, then reintroducing them one at a time.

Anti-inflammatory foods may help someone with arthritis manage their symptoms. These include plant-based foods, such as fruits, vegetables, whole grains, and anti-inflammatory fats.

Someone with arthritis who is struggling to find the best eating plan may wish to speak to a registered dietitian.

More:
5 foods to avoid with arthritis to reduce pain

Read More...

Arthritis: Signs and symptoms to look out for, treatment and tips to prevent – Times Now

August 17th, 2021 1:48 am

Arthritis: Signs and symptoms to look out for, treatment and tips to prevent | Photo Credit: Pixabay 

New Delhi:Joints, the point at which two bones meet, play an important role in the body's ability to move. Conditions affecting the joint can cause major discomfort and hindrance to lifestyle due to the obstruction in movement. Arthritis is a type of condition that affects the joints. The common areas that may be affected by this condition include hands, knees, feet, hips, and lower back. According to the Centers for Disease Control and Prevention (CDC), arthritis is one of the leading causes of work disability.

Common arthritis types include osteoarthritis, septic arthritis, gout, thumb arthritis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, and reactive arthritis. If you notice the following symptoms in your joints, consult a doctor:

The risk factors of arthritis may include sex, genetics, joint trauma or injury, age, and obesity. Treatment of this condition focuses on reducing joint damage, pain management, and symptoms regulation. It can be diagnosed through methods such as direct arthrography, radiography, musculoskeletal system MRI, CRP test, and synovial fluid analysis. Depending on the type of arthritis, the treatment may involve physical therapy, medication, occupational therapy, occupational therapy, lifestyle regulation, and surgery.

Here are some tips for arthritis prevention:

Disclaimer: Tips and suggestions mentioned in the article are for general information purpose only and should not be construed as professional medical advice. Always consult your doctor or a dietician before starting any fitness programme or making any changes to your diet.

Link:
Arthritis: Signs and symptoms to look out for, treatment and tips to prevent - Times Now

Read More...

Psoriatic Arthritis Treatment Market demand has been rising on account of advancements in the field of healthcare and biosimilar analysis – BioSpace

August 17th, 2021 1:48 am

The occurrence of psoriatic arthritis can place an extremely negative toll on the overall health of individuals. This is because psoriatic arthritis is more severe than any other form of arthritis. Under psoriatic arthritis, patients suffering from a skin condition called psoriases start to exhibit extreme symptoms of arthritis. This results in excessive pain, uneasiness, and discomfort for the sufferer, often necessitating emergency dosage of steroids. Hence, there is a dire need to ensure that psoriatic arthritis is controlled which in turn gives an impetus to the growth of the global market. The revenue scale of the global psoriatic arthritis treatment market shall improve alongside advancements in the field of geriatric care.

There is no permanent treatment for psoriatic arthritis, and it can only be controlled with proper medication. The discomfort suffered by people affected with psoriatic arthritis is abysmal. Owing to the aforementioned factors, the global psoriatic arthritis treatment market is projected to attract the attention of the medical fraternity in the years to follow. The demand for psoriatic arthritis is projected to reach new heights in the years to follow.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5495

The global psoriatic arthritis treatment market can be segmented on the basis of the following parameters: drug class, route of administration, and region. Based on drug class, the global psoriatic arthritis treatment market can be segmented into Disease-modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Antiinflammatory Drugs (NSAIDs), and biologics. Based on route of administration, the global psoriatic arthritis treatment market can be segmented into orals, topical, and injectables.

Global Psoriatic Arthritis Treatment Market: Notable Developments

Several advancement in the competitive landscape have become a key characteristic of the global psoriatic arthritis treatment market in recent times.

Global Psoriatic Arthritis Treatment Market: Growth Driver

The occurrence of psoriatic arthritis is preceded by the severity of psoriasis in individuals. Hence, the field of dermatology needs to be work in conjunction with other medical departments in order to treat and control psoriatic arthritis. Hence, the global psoriatic arthritis treatment market shall expand alongside advancements in the field of dermatology. Furthermore, the availability of over-the-counter drugs for treatment of psoriatic arthritis propelled demand within the global market.

The joints suffer severe pain during psoriatic arthritis treatment, and the patients need to be quick recourse treatments. In a lot of cases, psoriatic arthritis poses a risk of permanent damage of joints. For this reason, the demand for psoriatic arthritis treatment has been rising at a stellar pace.

Global Psoriatic Arthritis Treatment Market: Regional Outlook

On the basis of geography, the global psoriatic arthritis treatment market can be segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Asia Pacific. The psoriatic arthritis treatment market in North America is expanding alongside advancements in the field of regional healthcare.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5495

The global psoriatic arthritis treatment market can be segmented as:

Route of Administration

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

More:
Psoriatic Arthritis Treatment Market demand has been rising on account of advancements in the field of healthcare and biosimilar analysis - BioSpace

Read More...

Arthritis symptoms: Five of the most common signs of arthritis you might be missing – Express

August 17th, 2021 1:48 am

Arthritis is a common health problem that causes pain and inflammation in joints. This condition is very common in the UK with more than 10 million Brits suffering from arthritis or other, similar conditions that affect the joints. Although arthritis can affect people of all ages it often emerges as you get older - here are five signs to spot the early onset of this debilitating condition.

Osteoarthritis is the most common type of arthritis it affecting almost 9 million in the UK alone.

The pain and stiffness commonly associated with arthritis emerge where the joints become inflamed, but there are other signs of this painful condition to watch out for.

There are lots of different types of arthritis and the symptoms you may experience will vary according to which type you have.

READ MORE:The 'ultimate' diet swaps and best foods to avoid arthritis symptoms

Sadly there isnt a cure for this condition but there are lots of treatments that can help to slow it down.

That is why its so important to seek diagnosis as soon as possible, the earlier you start treatment the better.

Treatments include medication, physiotherapy and in some cases surgery.

Surgical procedures such as hip replacements may be needed in the worse cases.

Being active and exercising regularly can help reduce and prevent pain.

The NHS say: "As long as you do the right type and level of exercise for your condition, your arthritis won't get any worse.

Combined with a healthy, balanced diet, regular exercise will help you lose weight and place less strain on your joints.

It adds: Your GP can recommend the type and level of exercise that's right for you.

Continued here:
Arthritis symptoms: Five of the most common signs of arthritis you might be missing - Express

Read More...

Best CBD Oils for Arthritis: Top Hemp Products for Joint Pain Reviews – The Daily World

August 17th, 2021 1:48 am

Arthritis is one of the top causes of disability in adults. With so many affected by this disease, one would think high-quality medication without side-effects is easy to find. However, that couldnt be further from the truth. OTC medications somewhat help, but they cause dependence and can even damage the liver. However, there is an alternative to common analgesics CBD oil. Using CBD to fight arthritis pain is a great natural option, and it has proven to be quite effective over the last few years. Still, you may be wondering What is the best CBD oil for arthritis on the market? Read on to find out.

Finding the best CBD oil for arthritis is harder than it seems. The oil needs to contain enough CBD to lessen the pain with frequent use. However, it should not contain more than 0.3% of THC because you should be able to use it whenever you need to without accidentally getting high. Additionally, all ingredients in the oil should be high-quality, preferably organic. Here are our top six best CBD oil for arthritis choices and what we love about each one:

If youre looking for the best CBD oil for arthritis that uses organic, high-quality ingredients, look no further. At Royal CBD, the quality of ingredients is something you can always count on. Although they are a relatively new company, Royal CBD has already differentiated itself as a premium manufacturer with effective products.

Although they also offer gummies, topicals, and capsules, CBD oils are their most sought-after product. However, theres a good reason for that, as all of the ingredients they use are GMO-free and organic. They source their hemp from certified organic farms in Colorado and use a supercritical CO2 extraction process. That way, they make sure to preserve as much of the active compounds found in hemp as possible.

The Royal CBD oils are full-spectrum, and they contain over 80 active compounds, in addition to CBD. However, they contain less than 0.3% of THC, so you wont have to worry about accidentally getting high from the oil. Royal CBD offers four potencies, ranging from 250 mg to 2500 mg. Additionally, they offer four flavor options mint, vanilla, berry, and natural. Every Royal CBD product is third-party lab tested for purity and quality. That means youll always get the high-quality oil you paid for.

Gold Bee offers a variety of CBD products that can help ease the symptoms of your arthritis. In their CBD range, you can find honey sticks, soft gels, gummies, and oils. Staying true to their name, all of Gold Bees products are honey-infused. If youre looking for the best CBD oil for arthritis that has a delicious, all-natural taste, Gold Bee CBD oil is the one to try.

The Gold Bee CBD oil comes in two flavors natural and kiwi-honey. However, if youre vegan, you should be cautious when shopping on their website. Although it says that their products are 100% vegan, many vegans choose not to eat honey, as it is a byproduct of bees.

If you are vegan and choose not to eat honey, unfortunately, you wont have any flavor options to choose from. Still, the unflavored oil is delicious, made out of organic, vegan ingredients, and one you must try. Its hard to find a completely vegan CBD oil, and this one contains a full-spectrum of hemp compounds that are quite effective.

Gold Bee Oils come in only one potency 1200 mg. That means you get about 40 mg of CBD per serving, which may be more than you need if youve never used CBD oils before. However, if you frequently use CBD products, the Gold Bee oil is a high-quality one you wont regret trying.

If youre looking for the best CBD oil for arthritis and youre new to CBD products, CBDPure oils may be perfect for you. Particularly, the 300 mg potency oil is one you must try. Since it delivers only 10 milligrams of CBD per serving, you wont be at risk of taking more than you need. Once youre used to CBD and how it makes you feel, you can increase the potency to 600, or even 1000. The 600 potency option contains 20 mg of CBD per serving, while the 1000 mg one has about 33 mg.

At CBDPure, every product is full spectrum. That means the natural terpenes and phytonutrients stay in the oil and aid in the absorption of CBD. They use organic hemp grown on family farms in Washington and Colorado. Additionally, they only work with farms they fully trust and have been using the same farm sources since 2016.

The extraction process is 100% based on supercritical CO2. Therefore, all of the CBD molecules and other compounds remain intact. Still, you wont be able to find an oil with a potency higher than 1000 mg at CBDPure. Additionally, they dont offer any flavor options, which may deter some from trying their products.

Hemp Bombs are one of the pioneers of the CBD products space. The company started working in 2016, and, since then, theyve been coming up with ways to include original flavors and higher potencies into their products. If youre looking for the best CBD oil for arthritis and you want a variety of potencies and flavors, Hemp Bombs can be a one-stop-shop for your every need.

They offer potencies ranging from 125 mg all the way up to 5000 mg. That means youll be able to get the dosage just right for your needs. Furthermore, Hemp Bombs products offer highly potent options at quite a reasonable price. They source their hemp from farms that use soil without pesticides, toxins, or heavy metals. However, their products arent certified organic, or GMO-free which is something to be mindful of.

Hemp Bombs CBD oils come in six flavor options. You can choose from five delicious flavors or go with a natural option that does not contain any artificial flavorings. However, if you dont mind artificial flavorings, you can choose a peppermint, watermelon, orange creamsicle, acai berry, or mint chocolate flavor. Hemp Bombs oils are inexpensive, delicious, and high-potency. They are a must-try if you like to try new flavors of CBD oils.

Medterra offers a wide variety of CBD products. If youre looking for the best CBD oil for arthritis, you should make sure its a broad or full spectrum. That means the oil contains helpful compounds such as CBC, CBG, and CBN, in addition to CBD. Still, you should make sure the oil contains less than 0.3% of THC in order to avoid the psychoactive effects of this compound.

Medterras products offer you ultra broad-spectrum CBD oils that contain many beneficial compounds found in hemp. Additionally, there are a lot of options to choose from. Their Ultra Broad Spectrum Cannabinoid Tincture comes in three flavors citrus, strawberry mint, and unflavored. You can also choose from two potencies, 1000 and 2000 mg.

If youre looking for a way to boost your immune system and fight arthritis pain, the Medterra Immune Boost Drops are a must-try. It comes in a 750 mg potency, and it contains healthy ingredients such as ginger root, elderberry, vitamins C and D, and many more.

Another noteworthy tincture from Medterra is the CBD Oil Tincture. It contains 99.6% CBD and organic MCT derived from coconut oil. Additionally, it comes in three potencies 500, 1000, and 3000 mg.

Nuleaf Naturals offers a wide variety of high-quality hemp products. In addition to CBD oil, they offer CBC, delta 8 THC, CBG, and CBN oil varieties. Additionally, they offer CBD pet oil, which can be highly beneficial to pets with arthritis. If youre searching for the best CBD oil for arthritis thats high quality but still inexpensive, Nuleaf Naturals is a great one.

When shopping for a Nuleaf Naturals CBD oil, you can choose from five potency options 300, 900, 1800, 3000, and 6000 mg. Additionally, you can get a single bottle of the oil, or opt for a 2-bottle or a 6-bottle bundle that will save you some money. However, the oils dont come in any flavors, which can be a deterrent for those who dont like the taste of CBD.

The oils Nuleaf Naturals offer are full-spectrum. That means youll get the benefit of the entourage effect because the hemp components will work in synergy. Additionally, they use supercritical and subcritical CO2 extraction methods, which preserve the biggest amount of CBD and other compounds. Furthermore, Nuleaf Naturals test their products in an independent lab making sure the quality and potency are up to par.

Arthritis is a disease that causes pain and swelling of the joints. It can also lead to loss of function in the joints, usually the knees or wrists. There are two common types of arthritis osteoarthritis and rheumatoid arthritis.

There is no clear cause of rheumatoid arthritis. Its an autoimmune illness that usually affects larger joints such as hips, knees, or elbows. Osteoarthritis has a clear cause, and its usually an injury or the wear of joints. It usually starts later in life, and its most common in athletes and the elderly.

If youre looking for the best CBD oil for arthritis, you may want to learn more about how CBD helps with arthritis pain. Cannabidiol is anti-inflammatory and, although the research on using CBD for pain management is still in its infancy, the results are promising. In 2016, researchers found that using CBD topically to the affected areas lessens arthritic pain. Additionally, a 2017 paper concluded that using CBD to manage pain connected to arthritis is effective and safe.

CBD oils are a great alternative to traditional pain medicine. However, its important to find the right CBD oil. Using low-quality oils can lead to a lack of positive effects. Therefore, many are discouraged after trying a low-quality CBD oil and choose not to give another oil a shot. That can lead to them choosing medication with potential side-effects instead of going for the natural option.

Choosing the best CBD oil for arthritis can make all the difference in whether the oil lessens your pain. Thats why you should choose carefully. However, if you stick to one of these highly potent oils, you cant go wrong. Pick the flavor you like and the potency that works for you, and enjoy a pain-free life without medication.

See more here:
Best CBD Oils for Arthritis: Top Hemp Products for Joint Pain Reviews - The Daily World

Read More...

Arthritis: A type of milk which may reduce your painful symptoms and what to avoid – Daily Express

August 17th, 2021 1:48 am

Arthritis is an umbrella term for a range of conditions that cause pain and inflammation in a joint. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting nearly nine million people. According to the NHS, OA initially affects the smooth cartilage lining of the joint - this makes movement more difficult than usual, leading to pain and stiffness. Milk and dairy products help to keep bones strong but what is the best type of milk for those suffering with arthritis symptoms according to experts and what should be avoided?

There are also claims that avoiding dairy can help with osteoarthritis, said Medical News Today.

The site continued: Although milk, cheese, and other dairy products can be problematicfor some people, these foods can have anti-inflammatory effects in others.

People who have inflammatory symptoms relating togout find skimmed and low-fat milkprotectiveagainst this condition.

An elimination diet can help people to determine whether or not their symptoms improve or worsen with dairy intake.

A study reported in the June issue of Arthritis Care & Research found that women who drank low-fat or skim milk experienced a slower progression of knee osteoarthritis.

The study, which was conducted by researchers at Harvard Medical School, followed 2,148 participants with arthritis symptoms in their knees for four years.

Researchers measured the participants' joint space in the knee to see how much their osteoarthritis was progressing.

Narrowing of the joint space is a sign that osteoarthritis is getting worse, noted the study.

It concluded that the more milk women (but not men) drank, the less their joint space narrowed.

Tea is one of the most studied drinks when it comes to its benefits for arthritis patients, said the Arthritis Foundation.

The health charity continued: Green, black and white teas are all rich in polyphenols compounds from plants that have strong anti-inflammatory effects.

Green tea is generally viewed as the most beneficial of all because its active ingredient is a polyphenol known as epigallocatechin 3-gallate (EGCG).

EGCG has been shown to be as much as 100 times stronger in antioxidant activity than vitamins C and E with studies showing it also helps preserve cartilage and bone.

Soda and other sweet drinksare the main culprits when it comes to added sugars.

Anti-inflammatory diet experts often say you should cut out all added sugars, including agave and honey.

"The more simple sugars we consume, the more gunk our bodies produce as a result of multiple metabolic responses, said nutritionist Jaclyn London.

She added: This sets off a chain reaction that can increase free radicals, which can be damaging to healthy tissues, and inflammation-promoting cytokines proteins produced by our immune system, which can exacerbate the process of cellular damage.

Read more:
Arthritis: A type of milk which may reduce your painful symptoms and what to avoid - Daily Express

Read More...

Review: JustCBD gummies, creams help with arthritis and sleep – Fast Company

August 17th, 2021 1:48 am

Hussein Rakine was working in a warehouse several years ago that supplied smoking and vaping products to stores. He noticed shady characters trying to sell him on a product called cannabidiol, better known as CBD. Impressed by the purported benefits (pain relief, anxiety reduction, etc.), if not people peddling it him, Rakine decided to make his own, initially with one customer in mind.

[Photo: Dylan Rives/courtesy of JustCBD]My mom was on something like 26, 27 pills at the time for arthritis and other ailments. She was constantly drugged up, Rakine says. I thought CBD was something that might help her. But I couldnt find anything on the market that I was comfortable giving to my own mom.

Rakine started making his own CBD tinctures with honey. My mom is a big fan of honey, he notes. Before long, he graduated to trying out gummies, and soon felt confident in the efficacy of his products and the potential hole he could fill in the CBD space with his own company.

JustCBD launched in 2017 and has since carved out a space in the CBD industry, which is expected to hit $55 billion by 2028.

In addition to selling more than 350 products online, including gummies, topical treatments, and even pet treats, JustCBD is carried in 14,000 stores worldwide.

[Photo: courtesy JustCBD]Rakines hook? Focusing on CBD as a lifestyle brand. People are approaching CBD from this medicinal, almost pharmaceutical route, and I dont think thats where CBD stands, he says. I think people take CBD to improve their lifestyle and not necessarily as a curelet me wake up in the morning, take my daily CBD so I can feel better throughout my day. We looked at it like that from day one.

Much like Rakine, who was seeking a solution for his mother, I was on the hunt for something to help my dad with his wrist painand, according to my dad, JustCBDs products have helped him like no other topical treatments have.

My dad had carpal tunnel surgery in 2018. Between that and arthritis issues, his wrists and hands often wind up swollen, stiff, and throbbing. When I came across JustCBDs products, I figured Id send some to my dad, knowing hed be slow to try them (if at all) due to the misconception that CBD gets people high. After convincing my dadnay, my mom, who he lovingly refers to as Inspector 12 for her shrewd eye toward everythinghe tried the roll-on stick and relief cream and hasnt looked back.

[Photo: courtesy JustCBD]Ive been sending him different products to try since then, the most recent being the Ultra Relief CBD Gel. And, according to his review by text message: That stuff really works.

I started using JustCBD around the same as my dad to try and fix my horrendous sleep habits. Im in a perpetual losing game with my brain, which refuses to wind down properly at night. JustCBDs regular gummies generally did the trick. But the company recently dropped a formulation with melatonin, and Im a changed man.

Rakine says his team is able to think up new products and turn them around in three months max.

We embrace the fact that were a small business, he says of his 200-person outfit. Its fun to be able to go to a lab and say, Hey, we need to make a sleeping product, and then let their creativity run. I think with some of the more big businesses, you dont get that nimbleness. It really gives us a competitive advantage.

[Photo: courtesy JustCBD]Whats also putting JustCBD at a competitive advantage is a pending acquisition from publicly traded health and wellness company Jupiter Wellness. In April, Jupiter Wellness filed a letter of intent to acquire 51% of JustCBD for $30 million.

With the acquisition, Rakine is hoping to invest in marketing, as well as build a bigger manufacturing facility, which would give us the capability to scale and grow as some of these big-box stores begin to call us and recognize what CBD is, he says. The Walmarts and Walgreens and Targets of the world, we need to be prepared for the influx we think is coming very soon.

Fast CompanysRecommender section is dedicated to surfacing innovative products, services, and brands that are changing how we live and work. Every item that we write about is independently selected by our editors and, whenever possible, tested and reviewed. Fast Companymay receive revenue from some links in our stories; however, all selections are based on our editorial judgment.

See the article here:
Review: JustCBD gummies, creams help with arthritis and sleep - Fast Company

Read More...

Arthritis diet: The surprising food that may cause painful joint inflammation – ‘limit’ – Daily Express

August 17th, 2021 1:48 am

Arthritis is a common condition that causes pain, inflammation and stiffness in a joint. It can be the result of simple wear and tear or autoimmune conditions. What unites the different forms of arthritis is what you can do to mitigate the impact of joint problems.

While theres no miracle diet for arthritis, fortunately, many foods can help fight inflammation and improve joint symptoms.

"For starters, a diet rich in fruits, vegetables, fish, nuts and beans but low processed foods and saturated fat, is not only great for overall health, but can also help manage disease activity," advises the Arthritis Foundation (AF).

Many of these components can be found in a Mediterranean-style diet.

In fact, studies confirm that eating foods commonly part of the Mediterranean diet can benefit your joints as well as your heart, reports AF.

"However, being active can help reduce and prevent pain," notes the NHS.

Regular exercise can also:

"As long as you do the right type and level of exercise for your condition, your arthritis won't get any worse," explains the NHS.

"Your GP can recommend the type and level of exercise that's right for you."

View original post here:
Arthritis diet: The surprising food that may cause painful joint inflammation - 'limit' - Daily Express

Read More...

Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region – Global Forecast to 2026 – Cumulative Impact of COVID-19 – Yahoo…

August 4th, 2021 1:55 am

Primary Cells Market Research Report by Origin (Animal Primary Cells and Human Primary Cells), by Cell Type (Dermatocytes, Gastrointestinal Cells, and Heart Cells), by End-user, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

New York, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06087175/?utm_source=GNW

The Global Primary Cells Market size was estimated at USD 1,025.78 Million in 2020 and expected to reach USD 1,144.46 Million in 2021, at a Compound Annual Growth Rate (CAGR) 11.90% from 2020 to 2026 to reach USD 2,014.78 Million by 2026.

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:This research report categorizes the Primary Cells to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Origin, the Primary Cells Market was studied across Animal Primary Cells and Human Primary Cells.

Based on Cell Type, the Primary Cells Market was studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes is further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.

Based on End-user, the Primary Cells Market was studied across Life Science Companies and Research Institutes.

Based on Geography, the Primary Cells Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Primary Cells Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Primary Cells Market, including AcceGen, Allcells, American Type Culture Collection, Axol Bioscience Ltd., BioIVT, Biopredic International, BPS Bioscience, Inc., Cell Biologics, Inc., Corning Incorporated, Creative Bioarray, Epithelix SRL, Ixcells Biotechnologies, Lonza Group AG, Merck KGaA, Neuromics, Ppa Research Group, Inc., Promocell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Primary Cells Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Primary Cells Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Primary Cells Market?4. What is the competitive strategic window for opportunities in the Global Primary Cells Market?5. What are the technology trends and regulatory frameworks in the Global Primary Cells Market?6. What is the market share of the leading vendors in the Global Primary Cells Market?7. What modes and strategic moves are considered suitable for entering the Global Primary Cells Market?Read the full report: https://www.reportlinker.com/p06087175/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

View post:
Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo...

Read More...

Global Stem Cell Assay Market growth will help industry players with different potential opportunities to explore the market 2021-2027 The Manomet…

August 4th, 2021 1:55 am

TheStem Cell Assay market report offers insights about the marketstatistics based on data collected fromprimary and secondary researchby industry experts. The Global Stem Cell Assay market analysis report gives a detailed overview of the Stem Cell Assay sector, market segmentation, competitive analysis, and major industry developments. The Stem Cell Assay market research study is structured by the latest and most sophisticated methods to capture, process, measure, and evaluate market data. The Stem Cell Assay market report assesses the changing competitive fundamentals based on key market factors. The Stem Cell Assay market forecasts are offered based on historical and future prospects of supply and demand.also, representing the Stem Cell Assay Market Factor Analysis-Porters Five Forces, Supply/Value Chain, PESTEL analysis, CAGR value, product offerings, company landscape analysis, Market Entropy, CAPEX cycle, COGS Analysis, EBITDA analysis,Patent/Trademark Analysis, andPost COVID Impact Analysis.Key Leading Players having extreme Growth Rate in last Few decades includedGE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Bio-Techne Corporation, Cellular Dynamics International, Cell Biolabs, Hemogenix, Stemcell Technologies.The analysis has listed and evaluated all the key players in the Global Stem Cell Assay Market Compared them on the basis of different metrics such as annual sales shipments volume, historical growth rates, market revenue, and marketing strategies.This Stem Cell Assay industry study report proposes strategic plans to improve market positions for existing market participants.

In addition, the report will also include the computed expected CAGR of the Stem Cell Assay market on the grounds of the prevailing and earlier records in relation to the global market. Moreover, it also offers pin-point analysis for altering the competitive dynamics of the market that can further help in decision-making. It also assists in recognizing the key products and their growth potential during the projected period.

Download Free PDF Sample Report Here:-https://www.syndicatemarketresearch.com/sample/stem-cell-assay-market

( We are Providing a Free Sample copy as per your Research Requirement, also including Covid 19 impact analysis )

Dont miss out on the Analysis of business opportunities in the Stem Cell Assay Market. Speak to our analysts and gain vital industry insights that will help you for your business growth.

Syndicatemarketresearch analysts cover all key parameters required for COVID-19 effect on the business industry, economic implications their trends, factors, consumer behavior on shopping, the effect on spending lot of money on advertising and also on useful industries like medical, transportation, food and Beverage.The globally rising of the Bio crisis COVID-19 has many businesses are struggling and confused on what steps to take to minimize or maximize the economic impact.

Some of the key companies profiled in the global Stem Cell Assay market report include:GE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Bio-Techne Corporation, Cellular Dynamics International, Cell Biolabs, Hemogenix, Stemcell Technologies

Major parameters covered under these company profiles include revenues, gross profits, operating income, COGS, EBITDA, sales volume, product offerings, company landscape analysis, key strategic moves, key recent developments, and technological roadmap.

The global Stem Cell Assay market has been segmented in the following manner:

By Type:Dermatology Stem Cell Assay, Cardiovascular Stem Cell Assay, Central Nervous System Stem Cell Assay, Oncology Stem Cell Assay, Other

By Application:Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research, Other

Key regions covered in the world Stem Cell Assay market report include:

The five regions are in a turned segment into major countries and geographies. The key countries included in the global Stem Cell Assay market report includeU.S., Canada, Germany, UK, Italy, France, Spain, China, India, Southeast Asia countries, South Korea, Japan, Australia, GCC countries, Turkey, Brazil, Egypt, Mexico, and South Africa among others.

The main objective of the whole market research report is to help the customer understand business in terms of scope, growth potential, fragmentation, opportunities, key market developments, changing consumer preferences, and new technological trends in the Stem Cell Assay market. The Stem Cell Assay market evaluation report consists of historical and forecasted market data shown by pie charts, maps, graphs, and Phased opportunity analysis in the study.

Key take aways from the report:

To get Free Consultation about Report, Do Inquiry Here @https://www.syndicatemarketresearch.com/inquiry/stem-cell-assay-market

Reasons to buy the global Stem Cell Assay market report:

TOC of Report include-

1 Study Coverage1.1 Stem Cell Assay Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.4.1 Global Stem Cell Assay Market Size Growth Rate by Type (Dermatology Stem Cell Assay, Cardiovascular Stem Cell Assay, Central Nervous System Stem Cell Assay, Oncology Stem Cell Assay, Other)1.5 Market by Application1.5.1 Global Stem Cell Assay Market Size Growth Rate by Application (Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research, Other)1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Stem Cell Assay Market Size2.1.1 Global Stem Cell Assay Revenue 2013-20252.1.2 Global Stem Cell Assay Production 2013-20252.2 Stem Cell Assay Growth Rate (CAGR) 2018-20252.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)2.3.2 Key Stem Cell Assay Manufacturers2.3.2.1 Stem Cell Assay Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Stem Cell Assay Product Offered2.3.2.3 Date of Manufacturers Enter into Stem Cell Assay Market2.4 Key Trends for Stem Cell Assay Markets & Products

3 Market Size by Manufacturers3.1 Stem Cell Assay Production by Manufacturers3.1.1 Stem Cell Assay Production by Manufacturers3.1.2 Stem Cell Assay Production Market Share by Manufacturers3.2 Stem Cell Assay Revenue by Manufacturers3.2.1 Stem Cell Assay Revenue by Manufacturers (2013-2018)3.2.2 Stem Cell Assay Revenue Share by Manufacturers (2013-2018)3.3 Stem Cell Assay Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Stem Cell Assay Production by Regions4.1 Global Stem Cell Assay Production by Regions4.1.1 Global Stem Cell Assay Production Market Share by Regions4.1.2 Global Stem Cell Assay Revenue Market Share by Regions4.2 United States4.2.1 United States Stem Cell Assay Production4.2.2 United States Stem Cell Assay Revenue4.2.3 Key Players in United States4.2.4 United States Stem Cell Assay Import & Export4.3 Europe4.3.1 Europe Stem Cell Assay Production4.3.2 Europe Stem Cell Assay Revenue4.3.3 Key Players in Europe4.3.4 Europe Stem Cell Assay Import & Export4.4 China4.4.1 China Stem Cell Assay Production4.4.2 China Stem Cell Assay Revenue4.4.3 Key Players in China4.4.4 China Stem Cell Assay Import & Export4.5 Japan4.5.1 Japan Stem Cell Assay Production4.5.2 Japan Stem Cell Assay Revenue4.5.3 Key Players in Japan4.5.4 Japan Stem Cell Assay Import & Export4.6 Other Regions4.6.1 South Korea4.6.2 India4.6.3 Southeast Asia

5 Stem Cell Assay Consumption by Regions5.1 Global Stem Cell Assay Consumption by Regions5.1.1 Global Stem Cell Assay Consumption by Regions5.1.2 Global Stem Cell Assay Consumption Market Share by Regions5.2 North America5.2.1 North America Stem Cell Assay Consumption by Application5.2.2 North America Stem Cell Assay Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Stem Cell Assay Consumption by Application5.3.2 Europe Stem Cell Assay Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Stem Cell Assay Consumption by Application5.4.2 Asia Pacific Stem Cell Assay Consumption by Countries5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines5.4.12 Vietnam5.5 Central & South America5.5.1 Central & South America Stem Cell Assay Consumption by Application5.5.2 Central & South America Stem Cell Assay Consumption by Country5.5.3 Brazil5.6 Middle East and Africa5.6.1 Middle East and Africa Stem Cell Assay Consumption by Application5.6.2 Middle East and Africa Stem Cell Assay Consumption by Countries5.6.3 GCC Countries5.6.4 Egypt5.6.5 South Africa

6 Market Size by Type6.1 Global Stem Cell Assay Production by Type6.2 Global Stem Cell Assay Revenue by Type6.3 Stem Cell Assay Price by Type

7 Market Size by Application7.1 Overview7.2 Global Stem Cell Assay Breakdown Dada by Application7.2.1 Global Stem Cell Assay Consumption by Application7.2.2 Global Stem Cell Assay Consumption Market Share by Application (2013-2018)

8 Manufacturers ProfilesCompany Name8.1.1 Company Details8.1.2 Company Overview8.1.3 Company Stem Cell Assay Production Revenue and Gross Margin (2013-2018)8.1.4 Stem Cell Assay Product Description8.1.5 Recent Developmentand others

9 Production Forecasts9.1 Stem Cell Assay Production and Revenue Forecast9.1.1 Global Stem Cell Assay Production Forecast 2018-20259.1.2 Global Stem Cell Assay Revenue Forecast 2018-20259.2 Stem Cell Assay Production and Revenue Forecast by Regions9.2.1 Global Stem Cell Assay Revenue Forecast by Regions9.2.2 Global Stem Cell Assay Production Forecast by Regions9.3 Stem Cell Assay Key Producers Forecast9.3.1 United States9.3.2 Europe9.3.3 China9.3.4 Japan9.4 Forecast by Type9.4.1 Global Stem Cell Assay Production Forecast by Type9.4.2 Global Stem Cell Assay Revenue Forecast by Type

10 Consumption Forecast10.1 Stem Cell Assay Consumption Forecast by Application10.2 Stem Cell Assay Consumption Forecast by Regions10.3 North America Market Consumption Forecast10.3.1 North America Stem Cell Assay Consumption Forecast by Regions 2018-202510.3.2 United States10.3.3 Canada10.3.4 Mexico10.4 Europe Market Consumption Forecast10.4.1 Europe Stem Cell Assay Consumption Forecast by Regions 2018-202510.4.2 Germany10.4.3 France10.4.4 UK10.4.5 Italy10.4.6 Russia10.5 Asia Pacific Market Consumption Forecast10.5.1 Asia Pacific Stem Cell Assay Consumption Forecast by Regions 2018-202510.5.2 China10.5.3 Japan10.5.4 South Korea10.5.5 India10.5.6 Australia10.5.7 Indonesia10.5.8 Thailand10.5.9 Malaysia10.5.10 Philippines10.5.11 Vietnam10.6 Central & South America Market Consumption Forecast10.6.1 Central & South America Stem Cell Assay Consumption Forecast by Regions 2018-202510.6.2 Brazil10.7 Middle East and Africa Market Consumption Forecast10.7.1 Middle East and Africa Stem Cell Assay Consumption Forecast by Regions 2018-202510.7.2 GCC Countries10.7.3 Egypt10.7.4 South Africa

11 Value Chain and Sales Channels Analysis11.1 Value Chain Analysis11.2 Sales Channels Analysis11.2.1 Stem Cell Assay Sales Channels11.2.2 Stem Cell Assay Distributors11.3 Stem Cell Assay Customers

12 Market Opportunities & Challenges, Risks and Influences Factors Analysis12.1 Market Opportunities and Drivers12.2 Market Challenges12.3 Market Risks/Restraints12.4 Key World Economic Indicators

13 Key Findings in the Global Stem Cell Assay Study

14 Appendix14.1 Research Methodology14.1.1 Methodology/Research Approach14.1.1.1 Research Programs/Design14.1.1.2 Market Size Estimation14.1.1.3 Market Breakdown and Data Triangulation14.1.2 Data Source14.1.2.1 Secondary Sources14.1.2.2 Primary Sources14.2 Author Details14.3 Disclaimer

Read our other Report:-

Global Ultraviolet (UV) Disinfection Equipment Market Competitive Landscape, with advanced Knowledge and Tactics 2021*2027

https://www.openpr.com/news/2315385/global-rutile-market-statastical-data-analysis-by-market-cap

Contact Us:

Syndicate Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll Free No.1-855-465-4651

Mail id:sales@syndicatemarketresearch.com

Go here to read the rest:
Global Stem Cell Assay Market growth will help industry players with different potential opportunities to explore the market 2021-2027 The Manomet...

Read More...

US trade and investment in Africa – Brookings Institution

August 4th, 2021 1:55 am

Thank you very much, Chairman Van Hollen, Ranking Member Rounds, and distinguished members of the Subcommittee, for your extraordinary leadership on U.S. Trade and Investment with Africa. Your exemplary bipartisan work on Africa inspires many in the U.S. and abroad on how politics can be used to serve the greater good. I am incredibly honored and grateful for the opportunity offered to me by the members of the Senate Foreign Relations Committees (SFRC) Subcommittee on Africa and Global Health Policy to testify on U.S. Trade and Investment in Africa.

I am Landry Sign, Executive Director and Professor at the Thunderbird School of Global Management, Senior Fellow at the Brookings Institutions Africa Growth Initiative in the Global Economy and Development Program, and a member of the World Economic Forums Regional Action Group on Africa, and the World Economic Forums Global Future Council on Agile Governance.

Advancing trade, investment, and technology in Africa offers enormous economic growth and increased prosperity for both regions and is best realized through value-based foreign policy and a market-based model of development, education, and accountability. There is no better time to accelerate U.S. trade and investment in Africa than now. Despite Africas tremendous economic potential, the U.S. has lost substantial ground to traditional and emerging partners, especially China. Indeed, while recent trends indicate that the U.S. engagement with the region has fallen, it has not and should not cede its relationship with the region to other powers.

Importantly, the U.S. can build on new regional momentum to revive and strengthen its partnership with Africa for mutual prosperity, including building on the recent launch of the African Continental Free Trade Area (AfCFTA), and given the promise of the initiatives of the DFC, Prosper Africa, and the post-AGOA 2025 options. To do so means a shift in emphasis in the relationship to one more focused on value-based foreign policy,1and also building upon the areas of strength and convergence with African citizens preferences;2 such as trade, investment, technology, education, accountability, and a market-based model of development.

Borders frequented by trade seldom need soldiers.

-William Schurz, second President of the American Institute for Foreign Trade (now the Thunderbird School of Global Management)

Trade and investment are not just about money and prosperity. They also bring and support peace, stability, and security. In my book Unlocking Africas Business Potential,3I explore key trade and investment trends, opportunities, challenges and strategies, that illustrate the tremendous potential of Africa, and explain the complex competition between emerging and established powers on the continent. The following key trends are critical for policymaking given their implications for trade investment, economic transformation, inclusive prosperity, geopolitical dynamics, and mutual U.S.-Africa interests.

1. Africas economic transformation and business potential are more substantial than most people think: the worlds next growth market. Considered a hopeless continent in 2000 by The Economist, Africa has seen the two best cumulative successive decades of its existence in the 21st century. Trade in and with Africa has grown 300 percent in the last decade, outperforming global averages (196 percent).4It has become home to many of the worlds fastest-growing economies, offering unique opportunities for U.S. trade and investment. Moreover, Africa has tremendous economic potential and offers rewarding opportunities for local and global partners looking for new markets and long-term investments with some of the highest returns, but also the potential to foster economic growth, diversification, job creation, including for women and youth, and improved general welfare.

2. The fast population growth on the continent could be turned into demographic dividends, or threats to global prosperity and stability. Africa was home to 17 percent of the world population in 2020, and is expected to have 26 percent of the global population in 2050 (2.53 billion people).5If Africa is not successfully integrated into the global economy, there could be a major threat to global prosperity and stability. Citizens could be further subject to extreme poverty, fragility, violent extremism, illegal immigration, health challenges, among otherschallenges that many already face on the continent. If our goal is a prosperous and safe world, Africa must not be left behind.

3. The growth of household consumption and business spending: a unique opportunity for U.S. trade and investment. By 2050, Africa will be home to an estimated USD 16.12 trillion of combined consumer and business spending.67 And Africas prosperity can be good for the U.S.: Such growth will offer tremendous opportunities for U.S. businesses in household consumption (USD 8 trillion) in areas such as food and beverages, housing, hospitality and recreation, health care, financial services, education and transport, and consumer goods, but also business to business spending (construction, utility, and transportation, agriculture and agri-processing, wholesale and retail, etc.).

4. The rise of global partnerships and the competition between traditional and new players: an opportunity for the U.S. to build on its sustainable competitive advantage. In 2009, China became the regions prime trading partner. In fact, between 2006 and 2016, Chinas trade with Africa surged, with imports increasing by 233 percent and exports increasing 53 percent, as they did for several other global players as well.8 During the same period, the U.S. lost ground in exports to Africa (-66 percent).9

Chinas influence goes beyond the trade relationship: It is also the top investor in infrastructure, and now is the first destination of English-speaking African students, outperforming the U.S. and the U.K.10

Change (increase) in imports from Africa,

2006 2016

Change (increase) in exports to Africa,

2006 2016

Source: IMF, Direction of Trade Statistics, 2017.11

But the U.S. remains a critical player on the continent, as I mentioned in a recent article: Successes in the past decadesinitiatives such as the African Growth and Opportunity Act (AGOA), the Presidents Malaria Initiative, the Presidents Emergency Plan for AIDS Relief, the Millennium Challenge Corporation, and U.S. trade and investment hubshave generated tremendous opportunities for millions of Africans and Americans. But the current eraand competition from other global powerswill require new ideas and a new approach to several key issues.12 In fact, African countries would often prefer to work with the U.S. given local content regulation rules, more investment in on-the-ground resources, and standards about hiring/training locals. In other words, the U.S. is less extractive and more transparent than numerous other partners.

5. Fast urbanization but also fast rural population growth: By 2030, Africa will be home to 5 cities of more than 10 million inhabitants and 12 other cities of more than 5 million inhabitants.13 Cities in Africa are becoming powerful economic centers, and a city-based approach to foreign policy, but also trade and investment, will be critical to outperform competitors and build mutual prosperity. Contributing to the prosperity of African cities will also make a difference in addressing security challenges.

6. Africa has made tremendous progress in mobilizing resources for infrastructure development, working hard to bridge gaps in ICT, energy, water and sanitation, and transportation. Despite the remaining deficits, the Infrastructure Consortium for Africa (ICA) reported that between 2013 and 2017 the annual funding for infrastructure development in the region was USD 77 billion, about twice as much as the annual funding average of the first six years of the 2000s.14 However, many of these gaps persist. In 2018 the African Development Bank (AfDB) found that Africas infrastructure requirements are between USD 130 and 170 billion a year, leaving a financing gap of USD 68 to108 billion.15 China has played a key role in financing, and has become the largest bilateral infrastructure financer in Africa (Chinese FDI grew 40 percent annually from 2010 to 2020).16 However, the U.S. has the chance to make a monumental difference when it comes to investing in infrastructure development in Africa.

In fact, Africa has one of the fastest-growing, and is the second-largest, mobile phone market in the world.1718 In sub-Saharan Africa alone, there were 477 million mobile subscribers in 2019; by 2025, the region will host 614 million cell phone subscribers, and 475 million mobile internet users.19 The internet is also expected to contribute to at least 5 to 6 percent of Africas total GDP by 2025.20 While the Information and Communication Technology sector is making incredible advancements, water and sanitation, transportation, and energy infrastructure development still needs significant investment. However, this is indicative of positive and extensive investment opportunities that can be undertaken on the African continent.

7. Fast digitalization, increased technological innovation, and an accelerated Fourth Industrial Revolution (4IR): The Fourth Industrial Revolution is characterized by the fusion of the digital, biological, and technological world, and technologies such as artificial intelligence, big data, 5G, drones and automated vehicles, and cloud computing.21 As a world leader in technological innovation, digital transformation, and the Fourth Industrial Revolution, the United States is well-positioned to play a leading role in the African digital space and contribute to Africas pursuit of now-vital technologies.

Indeed, advanced technology can have beneficial spillover effects: For example, in health, countries such as Rwanda and Ghana are using an American drone company Zipline to deliver, in record time, medication, blood, and medical supplies to remote rural areas with limited road accessibility.22 In agriculture, African farmers now have access to affordable precision farming tools that use sensors, satellites, smart devices, and big data technologies to inform every decision. The lending, insurance, and e-commerce opportunities provided by the fintech industry are transforming the lives of all Africans, and not just those in urban centers. These advancements are just the beginning too, as African entrepreneurs are increasingly seeking partners to bring transformative businesses to life. African tech startup funding increased over 40 percent in 2020 to over USD 700 million, a fraction of tech startup funding outside of Africa. Despite such progress, the digital divide remains important and must be bridged to allow inclusive development. During the pandemic, for example, access to school and business on the continent was more complex given the level of internet connectivity, among other limitations. Bridging the digital divide represents an opportunity to both advance U.S. trade and investment in Africa while addressing some of Africas key priorities.

8. Fast regional integration and the African Continental Free Trade Areas: opportunities for a continental engagement. With the signing of the African Continental Free Trade Area (AfCFTA) in 2018, ratification in 2019, and an official launch in January 2021, African growth prospects and business opportunities have been magnified. The continent is giving the world just one more reason to invest in it with the creation of the largest new free-trade zone per number of countries in world, since the creation of the WTO. The AfCFTA will accelerate Africas industrialization as well as incomes, which will lead to the increase of both household consumption and business spending, generating unique opportunities for U.S. trade and investment. Per a World Bank study, the AfCFTA has the potential to lift 30 million people out of extreme poverty, increase the income of 68 million Africans, increase Africas exports by USD 560 billion, and generate USD 450 billion of potential gains for African economies by 2035.23

9. The sustained demand for accountability, democracy, and stability of African citizens, and policy priorities aligned with U.S. core values. Per Afrobarometer surveys, 7 out of 10 Africans support democracy and accountable governance, and approximately two-thirds are opposed to a single party or military government.24 Importantly, areas in which the U.S. has a sustained competitive advantage, given its global leadership in democracy and human rights, and its support for such issues as health and education, are priorities for Africans too.25Given Chinas leadership in infrastructure, the U.S. could grow its footprint in this area but by partnering with other players such as the G7 and the European Union countries. This approach will be welcomed by African citizens, who prefer the U.S. model of development (32 percent) over the Chinse one (23 percent).26

The pandemic has created unique momentum for engagement with Africa. The U.S. should seize this momentum and build on Congress historical bi-partisan support for the region to develop and successfully implement a long-term comprehensive Africa strategy that effectively coordinates action around trade, investment, commerce, and economic growth. This strategy should draw from consultations with African partners and multilaterals, building on areas of sustainable competitive advantages. The strategy should:

a) be rooted in the American values and principles that are aligned with the priorities of African citizens and U.S.-Africa mutual trade and investment interests

b) protect American, African, and global interests by advancing security, stability, and peace through strategic partnerships with African organizations

c) utilize U.S. strengths (digital transformation, Fourth Industrial Revolution, education, creative industries, health, democratic values, etc.) in the context of the new continental trade dynamics brought about by the African Continental Free Trade Areas (AfCFTA).

Importantly, these are areas where the U.S. can still outperform its main competitors such as China or Russia. More specifically, my recommendations to the Subcommittee are as follows:

1. Build on multilateralism and strategic alliances in concert with African partners to advance U.S. and African interests.

Given Africas own emphasis on regionalism, the U.S. would do well to support those efforts and align its own strategy with this perspective in mind. Core African partners include: the African Union, the African Continental Free Trade Area, the Africa Centres for Disease Control and Prevention, the African Union Development Agency, the African Development Bank, among others.

African leaders are looking for partners, especially in terms of trade and investment, more than they need aid. Initiatives from the Millennium Challenge Corporation and the DFC should further support African regional and continental projects, when possible, through regional compacts (MCC, through the 2018 AGOA and MCA Modernization Act, allows investments to be made across borders in Africa, creating opportunities for trade and investment by fostering regional integration and integrated markets).27 For the U.S. to outperform its competitors, it must be on the ground engaging with Africa both at the base but also at the highest levels, building on the Trade and Investment hubs, but going much further.

2. Enhance the effectiveness and better coordinate the action of U.S. agencies acting around trade and investment in Africa by adopting the principle of agile governance.

The U.S. already has phenomenal tools, which in principle, could make a monumental difference if successfully implemented. Prosper Africa holds a lot of potential in terms of trade, investment, shared prosperity, and effective coordination of U.S. agencies, which is not yet realized. The goal of Prosper Africa is to coordinate the tools from across government agencies28 and to foster trade and investment between the U.S. and Africa. Although it is a great idea, many players, especially on the African side, are still hoping for it to achieve its full potential. It will be extremely important to have major wins to reinstate trust with African partners.

I recommend making Prosper Africa more agile in its ability to manage complexity and competition, and appoint a dedicated full-time Chief Executive Officer to assist the current Executive Chairman and Chief Operating Officer, who are doing tremendous work. This new position should have the authority needed to fix the pacing (appropriate speed of action), coordination (legitimate and appropriate coordination), and representation challenges (uniqueness of the voice, communication, and acceptance of the credibility), to deliver exceptional outcomes for U.S. and African businesses, and investors, to achieve mutual prosperity.

3. Redefine the base for new engagement with Africa by appointing a U.S. Special Presidential Envoy for Africa to represent the U.S. at high-level meetings and multiply presidential and high-level visits in Africa.

To stop ceding ground to other powers in Africa, it is crucial that the U.S. reiterate the respect it has for Africa, Africans, and their leaders. Appointing a Special Envoy and reinstating high-level meetings, including presidential visits to the region, between the United States and Africa will send a strong signal. Regular visits by senior U.S. officials, including the President and his cabinet, will help to shift perceptions around Africa, highlighting the continent as a safe, reliable destination for investment. Creating a forum for dialogue between government officials and the SME community will create the opportunity to engage in a systematic and coordinated way.29

Advancing such levels of engagement, with specific actions, will substantially advance mutual interests. The U.S. should build on this to further institutionalize relations with Africa and engagements at the highest level. The success of the U.S.-Africa Business Forum, which did contribute to deals around USD 14 billion between 2014 (first edition) and 2016, with additional deals and commitments of USD 9 billion at the 2016 edition, illustrate the importance of high-level meetings, which should be reinitiated (The first edition of the U.S.-Africa Business Forum was attended by about 50 heads of state and governments, and 150 global CEOs).

This is not just important for African leaders, but also for African citizens who prefer the U.S. model of development compared to any other country.30Strategically seizing such as opportunity to build a long-term sustainable advantage will be critical.

4. For the successful implementation of the AfCFTA and other critical initiatives (post-2025 AGOA, among others) the U.S. should be involved in regular high-level consultations between the United States Trade Representative, the AfCFTA, and the African Union, creating a working group which could define the critical steps forward.

It is important to engage with Africa on the way forward about U.S.-Africa relations, through regular consultations. The AfCFTA offers new opportunities for U.S. businesses to use Africa as a global platform, not just to capitalize on the large African market, but to benefit from the unique advantage provided to sell around the world. The U.S. will also gain market shares, etc. Africa can become the base for U.S. companies to trade not just with Africa, but with the world as well. Africa is not just a market, but also a platform to manufacture and export in other regions of the world. The AGOA Forum provides a platform to discuss these questions in partnership with Africans, but it remains underutilized.

5. The U.S. should capitalize on the AfCFTA that provides the opportunity for the U.S. and the world to finally address the global macroeconomic imbalances which have been reflected in structurally large U.S. current account deficits with a handful of countries largely on account of excessive concentration of supply chains.31

The growth opportunities associated with increasing economies of scale and productivity growth under the AfCFTA provides the path to reorder and diversify the supply chains for greater resilience and while also sustainably addressing the macroeconomic imbalances which have dominated the world economy over the past decades.

Already several countries and corporations are taking advantage of growth opportunities offered by the AfCFTA in the automotive industry. Volkswagen has opened its first car plant in Rwanda.3233 Groupe Peugeot Socit Anonyme has established its first plant to assemble up to 5000 cars a year in Namibia, taking advantage of the free market area to target customers in other countries across the region.34 With its population growth and rising middle class, Africa could well become the largest market for the automotive industry in the coming decades.

These are tremendous opportunities that U.S. carmakers, including those manufacturing less polluting new energy vehicles should be targeting, especially with Africas excess reserves of lithium and coltan which are some of the most important raw materials for a rapidly changing industry.

6. Focus policy action on impact, and on the effective implementation and delivery of initiatives, not just on big policy announcements.

The U.S. should distinguish itself by focusing on successful implementation of existing or new initiatives. For example, the G7 countries and partners have announced an USD 80 billion dollars commitment for Africas private sector for the next five years. How will it be implemented? It is critical to have a clear mechanism for successful implementation that includes sufficient details about the projects. For example, the U.S. and partners should engage with African multilaterals (AfCFTA, AU, etc.) and governments during the policymaking and implementation processes to strategically identify and align objectives. An implementation unit may be created, and a multistakeholder working group to assess and decide on mutual priorities. Similarly, how could the Build Back Better World initiative be successfully implemented, and to what extent will Africa benefit from it? The administration needs to appoint a leader to strategically engage and to have consultations with allies. Bringing the allies together, and giving teeth to the plans that have been put together, will be critical to build sustainable competitive advantage for the U.S.

7. The U.S. should promote commercial diplomacy through an economic strategy that goes beyond the traditional vision of trade and investment. Domestically, the U.S. should increase efforts to document and disseminate the tremendous potential Africa can have for U.S. businesses.

Given that a central goal of Prosper Africa is to double two-way trade, the United States should play a better role in identifying and sharing business and investment opportunities with its domestic businesses and corporations. As large corporations are already better resourced when dealing in Africa, American SMEs are the most likely beneficiaries of Prosper Africawhether through market access or on the supply sideand the DFC should provide them with resources to help trade and invest in a timely manner. For Prosper Africa to benefitboththe U.S. and Africa, each side needs to feel confident in the trading process and consider each other a friend.

Prosper Africa should focus on specific mechanisms aimed at ensuring that American SMEs better understand the dynamics in Africa, to develop a specific interest and attraction on the continent and make others more eager to invest and do business there. This goal can be achieved throughbusiness promotion and facilitation activities encouraging business development as well as corporate diplomacy.

8. The U.S. should capitalize on the African Diaspora, which is heavily represented and active in the U.S., by specifically adopting diaspora commercial diplomacy to foster trade and investment between the U.S. and Africa.

President Biden has made steps in strengthening this relationship through early engagement with the community, but this strategy can be pursued further in regard to trade and investment with Africa in order to distinguish the U.S. from other competitors and accelerate its competitive advantage. The collaborations between African innovators on the continent and African and African-American innovators based in the U.S. have the potential to advance U.S.-Africa relations on several levels.35 Members of the African diaspora have an incredibly valuable understanding of Africa-U.S. cross-cultural engagement, not to mention existing relationships and networks on the continent, making them perhaps the best suited to Prosper Africas efforts to support and facilitate business I mentioned above. Prosper Africa should formalize a relationship with the African diasporas SME community and the continents SME community, and routinely engage as a group, to support the formulation of strategies and mechanisms to increase two-way trade. It has started such an effort, but can do more: For example, in 2019, Brookings hosted a conversation between USAID and members of the diasporas SMEs. It brought to light specific, actionable ways to enhance the programs mechanisms, including the need to expand staff support at trade hubs, expedite DFC loans, and improve data collection and analysis.36 SMEs in Africa are crucial to include in these conversations so that all stakeholders are involved to ensure Prosper Africa designs effective, efficient policies.

9. Accelerate the COVID-19 vaccine strategy and partnerships, and aggressively pursue vaccine diplomacy beyond COVID-19 by supporting the development of a vaccine manufacturing industry in Africa, including investments in human capital and technology development.37

According to the Africa Centers for Disease Control and Prevention (Africa CDC), only 3.19 percent of Africans have received at least one dose of the COVID-19 vaccine as of July 21, 2021.38 A Duke University study estimated that most Africans will not have had an opportunity to receive the COVID-19 vaccine until 2024.39 The devastation of the COVID-19 pandemic, as well as other epidemics in recent years like, has revealed the urgent need for investment in Africas national and continental healthcare systems. Vaccine diplomacy is a crucial first step towards helping Africa recover from the pandemic and prevent the emergence of new variants that might damage the recoveries in other nations.

While it is the right thing to do, it will also support U.S. businesses. Poor healthcare systems threaten Africas industrialization and workforce development, and now is the opportunity for the U.S. to help build equitable health systems and ensure preparedness for future health emergencies. This support should not be limited to loans or donations. Partnerships with academic institutions or public-private partnerships between U.S. and African agencies and firms that create avenues for collaboration, knowledge exchange, and skill and technology development will all be instrumental in strengthening the soft power of the U.S.

Specifically, the U.S. should provide broad technical and financial support for the new African Union-Africa CDC initiative, Partnerships for African Vaccine Manufacturing (PAVM), which aims to build five vaccine-manufacturing research centers over the next 10-15 years. The success of this PAVM initiative would open doors for a transformation of Africas pharmaceutical industry in Africa, a sector that has enormous growth potential. The development must go beyond fill and finish manufacturing, which does little to truly decrease Africas overreliance on foreign suppliers.40

10. Contribute to closing the gap in the physical and digital infrastructure by leveraging existing programs supporting African countries digital transformation strategies.41

The U.S. already has established infrastructure and technology development programs, but is underutilizing them. Such initiatives, especially those that focus on electricity and internet penetration, should be prioritized and fast-tracked.42

Most importantly and prior to even leveraging these existing initiatives, the U.S. should consult and act in partnership with African countries for the investments in major infrastructures, including 5G. For example, an opportunity is within OPIC [now DFC]s Connect Africa initiative, which was launched with a fund of USD 1 billion for transportation, ICT, and value chain development projects.43 The Power Africa initiative has been successful, and augmenting the program now would contribute to repairing and strengthening the U.S.-Africa relationship.44

Furthermore, several African countries are developing and implementing a multi-stakeholder Fourth Industrial Revolution (4IR) national task force or commission to assess country readiness and adopt a comprehensive national strategy. Initiatives such as the Centers for the Fourth Industrial Revolution (South Africa and Rwanda), or the Presidential Commission on the 4IR (South Africa) should be supported and replicated across the continent.

11. The U.S. must continue and increase its support to bridging the infrastructure gap in Africa while advancing trade and investment for mutual prosperity.

This, simultaneously, represents both a way forward to enhance trade and investment while achieving the global public good. In fact, in Sub-Saharan Africa, over 50 percent of people live without access to electricity, more than 70 percent of people live without access to safe drinking water, 69 percent of people live without basic sanitation,45 and 53 percent of the roads are unpaved.46 China has been playing a central role by investing in these areas.

Importantly, the U.S. should differentiate its approach from competitors by emphasizing engagement with African continental organizations (PIDA, the AFDB, the African Development Fund, among others), bilaterallyand more importantly, transparently, with specific countries, and by partnering with allies. The U.S. also could better support capacity building and regional projects through investments, new projects, and partnerships. The U.S. could better partner with Africa to bring its own expertise and knowledge to serve at various phases of project development, such as studies and implementation.47 A long-term partnership will also be key to outperforming other players. The U.S. will see a high return for its investments, as well as geostrategic balance. The U.S. will fill an empty seat, that would otherwise be occupied by other players on the continent.

12. The U.S. can build on higher education, another area of comparative advantage, to provide technical training and reskilling programs through initiatives and agencies to close the digital skills gap and human capital gap (especially for youth and women).48

It is crucial the U.S. expand educational and training opportunities in Africa. The soft skills and development of academic institutions provide the opportunity for the U.S. to lay the foundation for a lasting win-win partnership with Africa, sustained by knowledge exchange and deepening business ties. U.S. policy needs to provide support that incentivizes American universities to open more campuses and degree programs, especially in STEM and technology, throughout Africa. Such programs provide skills in areas critical for the rise of manufacturing industry and effective decentralisation of global supply chains and will be equally beneficial learning opportunities for African students and American students who may study abroad. For example, Carnegie Mellon University has a campus in Rwanda that offers masters programs in information technology and electrical and computer engineering.49 Morgan State University has recently launched a partnership with a university in Ghana, offering two graduate degree programs to students.50 Fast-growing SMEs will be far more likely to evolve and invest in areas where there is a skilled workforce or, at least, resources to support training workers, and added U.S. support could go a long way towards creating an attractive business environment for SME investment. It is indeed an opportunity to establish a long-term partnership of a new nature between U.S. and Africa.

In closing, it is time for U.S. to reverse the trend in the ground lost in Africa as many traditional and emerging global powers are racing to capture Africas tremendous economic potential. The U.S. has a sustained competitive advantage to partner with Africa, advance U.S. trade and investment with the continent, while meeting the majority of Africans priorities. It is up to the U.S. to pursue the recommendations above and seize this unique momentum to advance mutual U.S.-Africa trade and investment interests. By acting promptly, and forging transformative partnerships aligned with African values, the U.S. has the opportunity to not only advance its own interests and contribute to the transformation of a continent that will make up nearly 40 percent of the worlds population by 2100, but also the opportunity to lead the way in building a more prosperous, democratic, secure, and stable world. As mentioned by William Schurz, borders frequented by trade seldom need soldiers.

Thank you very much for your attention and looking forward to your questions.

Continued here:
US trade and investment in Africa - Brookings Institution

Read More...

Half Abandon Metformin Within a Year of Diabetes Diagnosis – Medscape

August 4th, 2021 1:54 am

Nearly half of adults prescribed metformin after a new diagnosis of type 2 diabetes have stopped taking it by 1 year, new data show.

The findings, from a retrospective analysis of administrative data from Alberta, Canada, during 2012-2017, also show that the fall-off in metformin adherence was most dramatic during the first 30 days, and in most cases, there was no concomitant substitution of another glucose-lowering drug.

While the majority with newly diagnosed type 2 diabetes were prescribed metformin as first-line therapy, patients started on other agents incurred far higher medication and healthcare costs.

The data were recently published online in Diabetic Medicine by David J. T. Campbell, MD, PhD, of the University of Calgary, Alberta, Canada, and colleagues.

"We realized that even if someone is prescribed metforminthat doesn't mean they're staying on metformin even for a year...the drop-off rate is really quite abrupt," Campbell told Medscape Medical News. Most who discontinued had A1c levels above 7.5%, so it wasn't that they no longer needed glucose-lowering medication, he noted.

One reason for the discontinuations, he said, is that patients might not realize they need to keep taking the medication.

"When a physician is seeing a person with newly diagnosed diabetes, I think it's important to remember that they might not know the implications of having a chronic condition. A lot of times we're quick to prescribe metformin and forget about it...Physicians might write a script for 3 months and three refills and not see the patient again for a year...We may need to keep a closer eye on these folks and have more regular follow-up, and make sure they're getting early diabetes education."

Side effects are an issue, but not for most. "Any clinician who prescribes metformin knows there are side effects, such as upset stomach, diarrhea, and nausea. But certainly, it's not half [who experience these]...A lot of people just aren't accepting of having to take it lifelong, especially since they probably don't feel any better on it," Campbell said.

James Flory, MD, an endocrinologist at Memorial Sloan Kettering Cancer Center, New York City, told Medscape Medical Newsonly about 25% of patients taking metformin experience gastrointestinal side effects.

Moreover, he noted that the drop-off in adherence is also seen with antihypertensive and lipid-lowering drugs that have fewer side effects than metformin. He pointed to a "striking example" of this, a 2011 randomized trial published in the New England Journal of Medicine, and as reported by Medscape Medical News, showingoverall rates of adherence to these medications was only around 50%, even among people who had already had a myocardial infarction.

"People really don't want to be on these medications...They have an aversion to being medicalized and taking pills. If they're not being pretty consistently prompted and reminded and urged to take them, I think people will find rationalizations, reasons for stopping...I think people want to handle things through lifestyle and not be on a drug," noted Flory, who has also published on the subject of metformin adherence.

Moreover, Flory explained, "These drugs don't make people feel better. None of them do. At best they don't make you feel worse. You have to really believe in the chronic condition and believe that it's hurting you and that you can't handle it without the drugs to motivate you to keep taking them."

Communication with the patient is key, he said.

"I don't have empirical data to support this, but I feel it's helpful to acknowledge the downsides to patients. I tell them to let me know [if they're having side effects] and we'll work on it. Don't just stop taking the drug and never circle back." At the same time, he added, "I think it's important to emphasize metformin's safety and effectiveness."

For patientsexperiencing gastrointestinal side effects, options including switching to extended-release metformin or lowering the dose.

Also, while patients are typically advised to take metformin with food, some experience diarrhea when they do that and prefer to take it at bedtime than with dinner. "If that's what works for people, that's what they should do," Flory advised.

"It doesn't take a lot of time to emphasize to patients the safety and this level of flexibility and control they should be able to exercise over how much they take and when. These things should really help."

Campbell and colleagues analyzed 17,932 individuals with incident type 2 diabetes diagnosed between April 1, 2012 and March 31, 2017. Overall,89% receivedmetformin monotherapy as their initial diabetes prescription, 7.6% startedmetformin in combination with another glucose-lowering drug, and 3.3% were prescribed a nonmetformin diabetes medication. (Those prescribed insulin as their first diabetes medication were excluded.)

The most commonly coprescribed drugs with metformin were sulfonylureas (in 47%) and DPP-4 inhibitors (28%). Of those initiated with only nonmetformin medications, sulfonylureas were also the most common (53%) and dipeptidyl peptidase-4 (DPP-4) inhibitorssecond (21%).

The metformin prescribing rate of 89% reflects current guidelines, Campbell noted.

"In hypertension, clinicians weren't really following the guidelines...they were prescribing more expensive drugs than the guidelines say...We showed that in diabetes, contrary to hypertension, clinicians really are generally following the clinical practice guidelines...The vast majority who are started on metformin are started on monotherapy. That was reassuring to us. We're not paying for a bunch of expensive drugs when metformin would do just as well," he said.

However, the proportion who had been dispensed metformin to cover the prescribed number of days dropped by about 10% after 30 days, by a further 10% after 90 days, and yet again after 100 days, resulting in just 54% remaining on the drug by 1 year.

Factors associated with higher adherence included older age, presence of comorbidities, and highest versus lowest neighborhood income quintile.

Those who had been prescribed nonmetformin monotherapy had about twice the total healthcare costs of those initially prescribed metformin monotherapy. Higher healthcare costs were seen among patients who were younger, had lower incomes, higher baseline A1c, had more comorbidities, and were men.

Campbell noted that "a lot has changed since 2017...At least in Canada, the sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists were supposed to be reserved as second-line agents in patients with cardiovascular disease, but more and more they're being thought of as first-line agents in high-risk patients."

"I suspect as those guidelines are transmitted to primary care colleagues who are doing the bulk of the prescribing we'll see more and more uptake of these agents."

Indeed, Flory said, "The metformin data at this point are very dated and the body of trials showing health benefits for it is actually very weak compared to the big trials that have been done for the newer agents, to the point where you can imagine a consensus gradually forming where people start to recommend something other than metformin for nearly everybody with type 2 diabetes. The cost implications are just huge, and I think the safety implications as well."

According to Flory, the SGLT2 inhibitors "are fundamentally not as safe as metformin. I think they're very safe drugs large good studies have established that but if you're going to give drugs to a large number of people who are pretty healthy at baseline the safety standards have to be pretty high."

Just the elevated risk of euglycemic diabetic ketoacidosis alone is reason for pause, Flory believes. "Even though it's manageable...metformin just doesn't have a safety problem like that. I'm very comfortable prescribing SGLT2 inhibitors, but If I'm going to give a drug to a million people and have nothing go wrong with any of them, that would be metformin, not an SGLT2 [inhibitor]."

Campbell and colleagues will be conducting a follow-up of prescribing data through 2019, which will of course include the newer agents. They'll also investigate reasons for drug discontinuation and outcomes of those who discontinue versus continue metformin.

Campbell has reported no relevant financial relationships. Flory consults for a legal firm on litigation related to insulin analog pricing issues, not for or pertaining to a specific company.

Diabet Med. Published online June 16, 2021. Abstract

Miriam E. Tucker is a freelance journalist based in the Washington DC area. She is a regular contributor to Medscape, with other work appearing in the Washington Post, NPR's Shots blog, and Diabetes Forecast magazine. She is on Twitter: @MiriamETucker.

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

See the original post:
Half Abandon Metformin Within a Year of Diabetes Diagnosis - Medscape

Read More...

Page 165«..1020..164165166167..170180..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick